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ABSTRACT (GERMAN) 
Die Entwicklung einer Zubereitung zur dermalen Applikation von Proteinen eröffnet 
einerseits neue therapeutische Möglichkeiten, stellt andererseits allerdings auch 
neue Herausforderungen an den Prozess der Formulierungsentwicklung. Neben dem 
hohen Molekulargewicht erschwert die hydrophile Struktur sowie die Sensibilität 
äußeren Einflüssen gegenüber die Verarbeitung von Proteinen und führt häufig zu 
einer kürzeren Haltbarkeit des Produktes. Zum Beispiel kann die hohe 
Hydrolyseanfälligkeit einiger Proteine zu Instabilitäten im Produkt führen und wurde 
exemplarisch in dieser Studie für die Familie der Kollagenasen untersucht. Um 
erfolgreich ein System zur dermalen Gabe zu entwickeln, muss außerdem eine gute 
Verträglichkeit auf der Haut gewährleistet werden können.  
Mikroemulsionen (ME), oder genauer gesagt Prä-Mikroemulsionskonzentrate, 
wurden als sehr vielversprechende Darreichungsformen für die Verarbeitung 
hydrolytisch anfälliger Proteine ausgewählt. ME entstehen spontan, direkt nach der 
Vereinigung aller Inhaltsstoffe ohne dass zusätzlich ein hoher Energieeintrag nötig 
ist. Diese Eigenschaft wird genutzt, um das Protein getrennt von der hydrophilen 
Phase zu verarbeiten. Lipophile und hydrophile Inhaltsstoffe befinden sich in zwei 
voneinander getrennten Kammern, wobei das Protein suspendiert in der lipophilen 
Phase vorliegt. Die Vereinigung der beiden Prä-Mikroemulsionskonzentrate zur 
finalen ME und damit auch das Lösen des Proteins, finden erst kurz vor der 
Applikation auf die Haut statt. Dadurch wird die Kontaktzeit zwischen Protein und 
Wasser und somit auch die Gefahr der hydrolytischen Zersetzung deutlich minimiert. 
Für die Bildung und Stabilisierung eines ME-Systems erwies sich das Phospholipid 
Lipoid® S LPC 80 (Lip80) als besonders gut geeignet. Neben den 
selbstemulgierenden Eigenschaften verfügt es über eine gute Hautverträglichkeit und 
kann die Penetration von Wirkstoffen in die Haut verbessern. Lip80 ermöglichte die 
Ausbildung von hydrophilen ME mit einem hohen hydrophilen Anteil von 60 %. Die 
Stabilität der Formulierung und ihre Eigenschaften als Trägersystem für Proteine 
wurden mithilfe eines Modelenzyms (Katalase) im Vergleich zu einer 
Referenzformulierung evaluiert. Als Referenz diente dabei eine ME, die mithilfe von 
PEGylierten Emulgatoren stabilisiert wurde.  
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Da Proteine über ein hohes Molekulargewicht verfügen, sind sie nicht dazu in der 
Lage durch Diffusion in die Haut einzudringen. Die äußerste Schicht der Haut, die 
Epidermis und hier insbesondere das Stratum corneum, fungieren als Schutzschicht, 
die es zu überwinden gilt. Dafür können z.B. Mikronadelsysteme verwendet werden, 
die die obere Hautschicht durchstechen. In dieser Arbeit wurde der Dermastamp® mit 
einer Nadellänge von 500 µm verwendet. Der Dermastamp® wurde gemeinsam mit 
der Lip80-ME und der Referenz-ME in einem 3D-Hautmodell auf Verträglichkeit 
geprüft. Evaluiert wurde die Verträglichkeit anhand immunologischer Faktoren wie 
der Zytokinausschüttung (IL-1α, IL-6, IL-8), der Zellviabilität (LDH) und anhand von 
morphologischen Veränderungen. Da bereits die Behandlung der Haut mit dem 
Mikronadelsystem lokal zu minimalen Verletzungen und damit zu Reizungen führt, ist 
der Einsatz einer milden Formulierung umso wichtiger.  
Bereits bei den Untersuchungen der Proteinstabilität und -aktivität zeigte die  
Lip80-ME deutlich überlegene Ergebnisse. Dieser Trend konnte auch durch die 
bessere Verträglichkeit im Hautmodell gegenüber der Referenzprobe bestätigt 
werden. Außerdem konnte durch Lip80-ME eine Abschwächung der durch das 
Nadelsystem zuvor erzeugten lokalen Irritation erreicht werden.  
Das entwickelte System aus Dermastamp® und Lip80-ME ist somit ein 
vielversprechender Ansatz für die dermale Applikation von (empfindlichen) Proteinen.  
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ABSTRACT 
The development of a dermal formulation containing a protein drug offers novel 
therapeutic options, but also comprises new challenges regarding the formulation 
development. Aspects to consider are the high molecular weight of proteins, the 
polarity and their sensitivity to external conditions which most often result in a short 
product shelf-life. Hydrolytic sensitivity can be one critical property of a protein that 
causes a decreased stability and hence has been examined exemplary for the family 
of collagenases in this study. To ensure the successful development of a vehicle 
system for the dermal delivery it must be tolerated well on human skin.  
Microemulsions (MEs) or more precisely pre-microemulsion concentrates were 
chosen as promising topical formulations for hydrolytic sensitive proteins. Due to their 
spontaneous formation after mixing the ingredients, MEs enable a separated storage 
of the aqueous and the lipophilic phase in a two-chamber-system. This special 
composition is utilised for the protein stability as the protein is suspended in the 
lipophilic phase during storage and only dissolved in the aqueous part of the ME 
shortly before the application. Therefore, the contact time between protein and water 
is reduced to a minimum. For the ME formation Lipoid® S LPC 80 (Lip80) was chosen 
as surfactant due to its high self-emulsifying power besides the enhanced skin 
penetration effects and good tolerability. Formulation stability and the ability to serve 
as protein vehicle system were analysed with a model enzyme (catalase) in 
comparison to a reference ME stabilised by PEGylated surfactants.  
Since proteins are high molecular weight drugs, a microneedle device supported the 
penetration to overcome the skin barrier. Dermastamp® (500 µm needle length) was 
selected and applied in combination with Lip80-ME as well as with the reference ME 
in tolerability studies with a 3D-full-thickness skin model. The immunological 
response was measured by the release of cytokines (IL-1α, IL-6, IL-8), the cell 
viability (LDH) and morphological changes. Microneedling is a minimal invasive 
procedure, stimulating a local irritation. Thus, the need for mild and well-tolerated 
formulations is even increased.  
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The stability and activity of model protein in Lip80-ME were more favourable than the 
reference ME. The superiority of Lip80-ME was confirmed by a lower irritation 
potential on reconstructed human skin. Moreover, this formulation showed the 
property to reduce the local irritation caused by the needle device.  
To sum up, the developed combination of Dermastamp® and Lip80-ME is a promising 
approach in the dermal application of hydrolytically sensitive proteins.  
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1 INTRODUCTION AND OBJECTIVES 
1.1 Introduction 
Peptides and proteins have become the drugs of choice for the treatment of 
numerous diseases. Advances in recombinant DNA-technology, improvements in 
large scale fermentation, purification processes and analytical characterisations 
widened the field of biopharmaceutics in the last years [1,2]. Compared to smaller 
synthetic molecules, protein-based therapeutic agents are believed to be highly 
specific and selective in their action besides a great effectiveness at lower 
concentrations. Furthermore, proteins are degraded into amino acids, without the 
enhanced risk of toxic metabolites [3].  
The number of protein and peptide drugs being placed on the market has been 
increased since 2000 [4]. Main fields of application are cancer, infections, and 
autoimmune diseases. To date the most feasible administration route of protein 
pharmaceuticals is the parenteral route. Drug degradation in the gastrointestinal tract 
either due to the acidic environment or enzymes and the avoidance of a first-pass 
effect make injections so effective. Many proteins have a short plasma half-life, thus 
requiring frequent injections. Therefore, alternative delivery methods that offer a 
more controlled release have drawn a lot of attention in research and development. 
Oral, nasal, transdermal and even buccal administrations are noninvasive, more 
patient-friendly and eliminate the need for medical assistance [5].  
This thesis will focus on the administration of proteins on skin with the possibility of a 
local or systemic therapeutic effect. The skin, being the most accessible organ of the 
body with a large surface area is an attractive option for the delivery of proteins and 
peptides for several reasons [6]. First, it avoids first-pass degradation by the liver or 
gastrointestinal tract and exhibits less enzymatic activity compared to mucosal 
routes. Second, a sustained or extended release of the drug will provide an option to 
deliver proteins with short plasma half-lives reducing the application frequency [7]. 
Dermal delivery improves patient acceptance and compliance because it enables a 
more convenient as well as painless administration compared to parenteral 
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administration. Furthermore, it provides an alternative to oral dosing in situations with 
unconscious or nauseated patients [8,9]. 
Proteins have a hydrophilic and flexible structure with a large molecular size, which 
results in a negligible penetration through the intact skin [7]. Tuan-Mahmood et al. 
(2013) emphasise the excellent barrier properties of the stratum corneum (SC) 
against high-molecular-weight drugs (> 500 Da) [10]. Several penetration 
enhancement techniques have been developed to overcome the SC and facilitate the 
transport of proteins into the skin. Commonly used strategies like chemical 
penetration enhancers and encapsulation in vesicles or nanoparticles, however, are 
unlikely to be effective for dermal delivery of high-molecular-weight drugs. For the 
dermal delivery of large molecules, the additional support of physical enhancement 
technologies e.g. electrically assisted (iontophoresis), mechanical (skin puncture) 
and miscellaneous methods (laser radiation) are needed [5,11]. Until now, these 
innovative technologies are not well-established on the world market. Various 
attempts were already made especially with iontophoresis patches to deliver small 
molecules such as lidocaine (LidoSite®, Vyteris, US) sumatriptan (Zecuity®, Teva 
Pharmaceuticals, US, suspended sale and marketing) and fentanyl (Ionsys®, The 
Medicines Company, US/EU, only dispensed in certified hospitals) [12,12,13].  
Zosano Pharma used skin microporation as a minimally invasive procedure for the 
development of a patch containing drug-coated microneedles capable of delivering a 
variety of drugs including biomolecules [14]. 3M has been working towards 
developing a hollow microstructured transdermal system for delivering liquid drug 
formulations into the skin [7]. Apart from the delivery of small molecules into and 
across the skin, biotherapeutics such as insulin, parathyroid hormone and vaccines 
have been delivered across the skin, too [15–18]. The usage of microneedles is 
versatile and many products are in the development stage as well as in clinical 
trials [19]. 
In this thesis, microneedle-based devices will be applied to facilitate barrier 
penetration, because of the easy handling and high efficacy beneath acceptable 
costs. The desired method involves a two-step approach, where the needles are 
used to puncture the skin to create micropores, followed by topical administration of a 
protein formulation. A topical protein-containing formulation should ensure high drug 
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stability, enable good solubility as well as spreading and penetration properties on 
patients` skin. This study will focus on the development of a topical formulation which 
facilitates the application of proteins with a high tendency for hydrolysis. Due to their 
instability in water bacterial collagenases appear to be good model proteins and will 
be utilised as references in this thesis.  
Collagenases are endopeptidases with a molecular weight of 70-120 kDa. They play 
an important role in turn-over processes of connective tissue. Collagens are major 
fibrous components of connective tissue and are digested by collagenases in the 
triple helix region. There are already products on the market e.g. for the treatment of 
wound healing processes (topical, Iruxol®, Smith and Nephew) and Dupuytren`s 
contracture (i.v., Xiapex®, Pfizer). Further clinical or cosmetic applications could be 
conceivable as the treatment of scar tissue or to stop aging processes in skin [20,21].  
Collagenases are stable as lyophilized powder over many years, whereas dissolved 
in an aqueous environment they show a significant loss of activity caused by 
autolysis [22]. Formulation development with collagenases is limited due to high 
costs of pure enzyme, expensive and time-consuming activity assays as well as 
stability analysis. To improve the efficiency and effectiveness in an early state of 
product development, collagenases were replaced by a model protein in this project. 
A molecular weight of 240 kDa (subunits 60-120 kDa), an easy, rapidly performed 
activity assay, besides a cheap commercially available quality make catalase a 
suitable model enzyme for the intended purpose [23].  
A “perfect” protein delivery system should ensure a high formulation and drug 
stability next to a favourable tolerability at the envisaged application site. The present 
study is based on the dermal application of a protein system which will be supported 
via a microneedling process. Bernhofer et al. (1999) stated that products designed 
for topical administration need to be safe and nonirritating. So-called skin tolerability 
tests are often included in first development steps of pharmaceutic and cosmetic 
dermal products to verify a product´s mildness [24]. To examine the irritation potential 
of developed application system on human skin these tolerability tests will be 
performed in the present study, too.  
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Since the early 1990s engineering initiatives have been started, focusing on 
producing 3D in-vitro reconstructed human skin models. Driving force was the 
demand to replace animal tests in skin tolerability studies. Skin equivalents 
composed of human-derived epidermal keratinocytes and dermal fibroblasts are fully 
immunocompetent systems capable of initiating and down-regulating an inflammatory 
reaction in response to external stimuli [25]. For the purposes of this thesis the 
presence of both epidermis and dermis is essential. On the one hand the higher skin 
thickness facilitates the formation of microchannels, on the other hand the interplay 
of keratinocytes and fibroblasts is necessary for the up-regulation and production of 
inflammatory mediators, especially cytokines. As consequence of the absence of 
visible symptoms in vitro (erythema and oedema) it is inevitable to investigate 
biomarkers to assess the irritant potential of a formulation system. In addition, the 
release of inflammatory markers is followed by morphological alterations, 
representing the beginning of typical symptoms of contact dermatitis on a cellular 
level [26].  
In short, protein drugs with their high target specificity and broad applicability have 
the potential to revolutionise medical therapy. Nevertheless, there is still a need for 
simple, reproducible strategies for the development and characterisation of protein 
formulations, e.g. facilitating the dermal application. Optimally, findings from this 
thesis can be adopted in the development of further systems and application sites. 
As protein stability in the vehicle system and the tolerability on human skin are first 
encompassing issues of dermal protein formulations, overcoming these challenges 
will likely lead to pharmaceutical formulations with great therapeutic potential.  
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1.2 Objectives 
This thesis focuses on the development of a topical formulation, which enables the 
application of hydrolytic sensitive enzymes. Furthermore, this study is an approach to 
address the challenges going along with dermal protein delivery, taking a look at 
special requirements of these drugs regarding the vehicle system and the application 
route (overcome the skin barrier) besides a formulation that is well tolerated on 
human skin. The development of an innovative dermal application system for 
proteins provides new treatment options in the field of dermatology. 
In order to obtain a skin-friendly formulation, mild excipients will be used. This is 
especially important because reducing skin barrier properties, e.g. by microneedling 
increases the irritation potential already. Reconstructed organotypic skin equivalents 
are a novel strategy to demonstrate the safety and non-irritating potential of topical 
products and will be utilised in this project.  
To realise the objectives, three target values have to be elaborated: 
The first part of this work will focus on the development and characterisation of a 
stable dermal formulation. Excipients have to be selected regarding their ability to 
form a suitable environment for the hydrophilic sensitive enzyme, enhance the 
penetration process and present a good tolerability on skin. The formulation will be 
characterised with analytical methods to demonstrate the stability of system beneath 
a high therapeutic activity of the incorporated protein drug.  
Second, a suitable microneedle device has to be evaluated. It will be chosen based 
upon its effectiveness and reproducibility forming microchannels through skin in vitro.  
In the final section of this thesis, the protein formulation will be applied in combination 
with the selected microneedle device on a reconstructed human skin model. 
Immunological markers and histological examinations will be evaluated to predict the 
in vivo tolerability on human skin.  
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2 PROTEINS FOR DERMAL APPLICATION  
2.1 Human Skin  
The skin, largest organ of the human body, comprises a surface area of 
approximately 1.5 m² to 2 m². It is a robust, flexible, and self-repairing barrier that 
protects the body from surrounding influences, harmful molecules as well as 
microbes. Its low permeability limits excessive water loss and helps to regulate body 
temperature. The skin forms an extensive sensory surface, permitting senses such 
as heat, cold, touch, pressure and pain [27,28].  
2.1.1 Structure and Function 
The ability of the skin to carry out multiple functionalities is related very closely to its 
structure. The skin can be divided into three main histological layers: the epidermis, 
the dermis and underneath the hypodermis (Figure 1).  
The hypodermis or subcutaneous fat layer is characterised by irregular arranged 
loose connective tissue with a high proportion of adipose cells and elastin. Due to the 
high content of adipose tissue it acts as heat isolator and shock absorber. The 
hypodermis carries most blood vessels as well as nerves within the skin, and 
contains sensory organs. In addition to the physical support, one further function is 
the provision of nutrients to upper skin layers [29].  
The dermis is located on top of the hypodermis with a thickness of approximately  
3-5 mm, depending on its location in the body [30]. It is divided roughly into an upper 
"papillary" and a lower "reticular" layer. Their names reflect the composition of 
connective tissue besides the supply of blood vessels and nerves, respectively. 
Despite the greater volume, the dermis contains fewer cells than the epidermis 
(Figure 1). 
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Figure 1. Schematic illustration depicting the structure of human skin. The skin is primarily composed 
of three layers: the epidermis, the dermis and the hypodermis. Different structures are composed of 
various cell populations e.g. keratinocytes, fibroblasts or immune cells. (Adapted from [11,29]) 
The main cell types that can be found within the skin are fibroblasts which produce 
and degrade extracellular matrix components. The extracellular matrix is a highly 
complex mixture of bioactive macromolecules which consists mainly of collagens but 
also of other components like elastin, fibrillin and proteoglycans. Embedded within 
this matrix are various structures, including nerve tissues, vascular/lymphatic 
systems and the base of skin appendages [31].  
Collagen fibres offer a mechanical and structural stability to the skin, whilst the elastic 
properties are associated with the presence of elastin. As presented in Figure 1 
several types of appendages are associated with the skin, e.g. hair follicles and their 
sebaceous glands as well as sweat glands. Sebaceous glands are formed as 
outgrowths of the hair follicle and secrete an oily material, the sebum, onto the skin 
surface. Sebum, a combination of various lipids, is a plasticiser for the stratum 
corneum (SC), maintaining an acidic protective mantle of pH 5 [32]. Sweat glands 
play an important role in the regulation of body temperature. They are responsible for 
the secretion and evaporation of sweat, stimulated by an increase of external 
temperature or emotional factors [31].  
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The blood vessels in the skin form a network which is responsible for the removal of 
toxins and waste products as well as the assistance in wound repair processes. This 
natural clearance can be utilised for percutaneous absorption of drugs into the 
systemic circulation and is additional supported by a lymphatic system [29].  
The contact with an exogenous substance (e.g. microbes, chemicals) can stimulate 
an immune response in the skin. Immune responses originating in the skin are 
mounted and executed by cells and molecules of either the innate or the adaptive 
immune system, whereby both are consecutive events influencing each other. The 
innate immunity presents the first line of defence, consisting of physical (stratum 
corneum as two-compartment system) and chemical barriers (epithelial and 
antimicrobial substances or an acidic pH value of five on the epithelial surfaces), 
phagocytic cells (neutrophils and macrophages), natural killer cells, the complement 
system and cytokines. In contrast, the adaptive immunity creates immunological 
memory after an initial response to a specific pathogen. In case of a secondary 
exposure to this known pathogen (antigen) the release of specific T cell or B cell 
derived antibodies is heightened [27]. Good examples for the cooperation of innate 
and adaptive immune system are dendritic cells. They are able to take up the 
antigen, process it and present it to T-lymphocytes in the draining lymphoid organs. 
Predominantly, two types of dendritic cells can found in human skin: epidermal 
Langerhans cells and dermal dendritic cells (Figure 1). Subcutaneous and muscle 
tissue contain only few dendritic cells, whereas the dermis and the epidermis are 
populated by a rich network. Due to the closed network residing in dermal and 
epidermal layers the human skin is an ideal target for the administration of antigenic 
agents [18,33].  
The basement membrane, a non-cellular layer separates the dermis from the 
outermost epidermis (Figure 1). The deepest layer of the epidermis is the basal layer 
or stratum germinativum, which is connected by hemidesmosomes to the basement 
membrane. Throughout the basal layer and higher epidermal layers, cells are 
connected via desmosomes. Besides basal keratinocytes, typical cells of basal layer 
are Merkel cells (apparent sensory functions), melanocytes (protection against 
damages caused by UV radiation) and Langerhans cells (immunological response) 
[29,31].  
Proteins for Dermal Application 
9 
 
The epidermis is the thinnest part of the skin with a thickness ranging from 60 µm on 
the eyelids to 800 µm on the palms [34]. Despite the extensive vasculature present in 
deeper skin tissues, the epidermis is avascular and the passage of materials into, 
through or out of it usually occurs by diffusion across the dermal-epidermal layer [29]. 
Figure 1 presents the composition of epidermis divided into viable layers (stratum 
basale, stratum spinosum and stratum granulosum) and a non-viable layer, the 
stratum corneum. The viable layers are composed of keratin-producing cells, called 
keratinocytes. Apart from their important role in maintaining the physical barrier of the 
skin, keratinocytes are an active participant in the innate immunity. They can produce 
antimicrobial peptides, cytokines, chemokines, and arachidonic acid metabolites [27]. 
After keratinocyte stimulation via a danger signal, e.g. skin irritation triggered by 
chemicals, the production and release of cytokines increase, leading to inflammation 
cascades like T cell activation and modulation of Langerhans cells. The cytoplasm of 
keratinocytes of all epidermal layers contains the pro-inflammatory cytokine IL-1α. 
Upon damage it leaks from the cells and induces the expression of secondary 
cytokines (e.g. IL-6 and IL-8). Furthermore, neighbouring keratinocytes respond to 
the damage with an increased production of IL-1α, as well as IL-1β, TNF-α and IL-6 
to amplify the immune response. This cellular cascade is followed by morphological 
alterations and may lead to typical symptoms such as oedema, erythema, itching or 
pain [26,35].  
Keratinocytes of the basal layer have stem cell-like properties and differentiate 
towards the skin surface (cornification). Cell regeneration or differentiation is a 
complex process in the epidermis, including dehydration and polymerisation of the 
intracellular material, that finally produces the cells of the SC [31].  
The SC or horny layer is the outermost layer of the skin. It mainly consists of dead, 
keratinised cells, called corneocytes. These cell layers are non-viable, yet flexible 
and biochemically active [30]. Classically, the SC structure can be described using a 
"bricks and mortar" model, the bricks representing the tightly packed corneocytes 
which are embedded in a mortar of lipid bilayers. The most important components of 
the lamellar structured lipid phase are polar ceramides. Especially the lipophilic 
nature and the unique architecture are responsible for the effective barrier properties 
of the skin against foreign substances including APIs. The permeation rate of a drug 
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through the SC strongly depends on its molecular weight (< 500 Da) and an 
adequate lipophilicity expressed as partition coefficient preferably between 1-3.5 
[10,11]. Transport into or through this layer primarily occurs by two known passive 
diffusion processes. Firstly, the molecule passes through keratinocytes and lipids in a 
straight way (transcellular route). Secondly, the molecule stays in the lipid bilayer and 
permeates around the keratinocytes into deeper layers (intercellular route) [36]. For 
large molecules (> 500 Da) with a hydrophilic nature like proteins and peptides both 
ways are impassable. Some of these limitations, however, can be overcome by skin 
permeability-enhancing techniques, which will be discussed in the following 
section 2.1.2.  
2.1.2 Strategies to Enhance Transdermal and Dermal Delivery 
There are large numbers of published studies describing the perfect barrier 
properties of skin and the problems associated with the delivery into and through it. 
Transdermal delivery describes the transport of an API through the various layers of 
skin into the blood circulation leading to a systemic therapeutic effect, e.g. treatment 
of pain with fentanyl. A local effect within the skin is described with the dermal 
delivery of a drug, in this case systemic absorption must be kept to a minimum. It is 
important in the treatment of dermatological conditions such as skin cancer or 
psoriasis [37].  
The need for strategies to overcome the SC barrier to facilitate a rapid and effective 
penetration of a broader range of molecules, including macromolecules is 
heightened. Such strategies that have emerged over the last years are summarised 
in Figure 2 and divided in passive and active methods [11]. 
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Figure 2. Overview of several strategies for enhancing transdermal and dermal delivery of 
macromolecules across the skin. (Adapted from [5,11]) 
Passive methods include the conventional way of drug application in a semisolid 
dosage form like a cream or gel. More recently these vehicles have been developed 
and modified for the transport of macromolecules such as proteins and peptides. This 
approach includes the encapsulation in vesicular carrier systems, e.g. liposomes, the 
use of penetration enhancers or chemical modifications and more lipophilic 
analogues [11,38]. However, the amount of drug that can be delivered is still limited 
because these modifications do not significantly disrupt the skin barrier. Passive 
delivery strategies might be only effective for the transport of small molecules 
(< 500 Da). Alternative enhancement technologies named as active methods, 
increase the penetration of the drug using physical energy or physical abruption of 
the SC. Prominent examples are presented in Figure 2, they use different sources of 
energy, e.g. small voltage constant current to push charged molecules into the skin 
(iontophoresis), ultrasound waves (sonophoresis) or the effect of elevated 
temperature (thermophoresis) to enhance the drug delivery [5].  
Apart from the mentioned techniques above, an enhanced API delivery into the skin 
can also be achieved using microneedles (MNs). This minimal invasive procedure is 
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utilised in the present study to support the dermal penetration of proteins and will 
therefore be explained in more detail.  
MNs are tiny micronised structures that pierce the SC and create microchannels for 
delivery of low and high molecular weight drugs. Typically, MNs range in their height 
from 100-1000 µm, shorter needles are not effective, because of the elastic nature of 
skin [29]. In case of longer MNs the risk of bleeding and pain increases, while 
patients` compliance decreases. Furthermore, MNs have been produced and 
examined in various geometries (e.g. sharp-, tapered-, conical- or bevel-tipped) as 
well as needle materials. Different materials exhibiting a range of properties, 
including metal, silicon, carbohydrates and polymers were processed for the 
production of MNs [10]. Figure 3, A depicts a microneedle array with 16 stainless 
steel needles, arranged in two rows (sample for research purposes, Dermaroller 
GmbH, Wolfenbüttel, Germany). Each needle has a length of 500 µm and a conical 
shape, tapering towards the tip (Figure 3, B).  
 
Figure 3. Sample of a microneedle array for research purposes. 16 needles (500 µm in height) are 
arranged in two rows (A). Image (B) presents a microscopic magnification of one microneedle with a 
conical shape, tapering towards the tip. (Scale bar = 200 µm) 
The application of each material and shape depends on the chosen design of MN 
device. Generally, there are two main categories, solid or hollow MNs, with the 
possibility of further modifications. The use of solid MNs is also termed as "poke with 
patch" approach, which means upon removal of MNs, transient microchannels are 
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created in the skin and a drug formulation can subsequently be applied (Figure 4, A) 
[39]. The drug penetrates through the microchannels via passive diffusion into the 
skin, typically out of a reservoir like a patch or topical formulation. Ding et al. (2009) 
investigated immune responses in mice following MN-mediated transcutaneous 
immunisation with diphtheria toxoid as model antigen [40]. Stainless steel MNs 
(4 x 4, 300 µm in height) were used to pierce the mouse skin and diphtheria toxoid 
was administered as solution afterwards. The immune response (measured as IgG 
titres) was significantly higher after MN treatment [40]. Although solid MNs are 
versatile and easy to use there are limitations, e.g. the two-step application process 
which may lead to practicality issues for the end-user [10]. 
Figure 4, B shows solid MNs coated with a drug formulation. This modification is 
termed "coat and poke" and enables after piercing the deposition of drug in the skin 
upon dissolution of the coating material [39]. 
 
Figure 4. Schematic representation of four different MN designs. Picture (A) shows solid MNs create 
micro-holes into the skin, (B) MNs are coated with a drug solution, (C) MNs are dissolvable and the 
drug is incorporated within the needles and finally (D) depicts hollow MNs which create microchannels 
and facilitate an active transport of the drug solution into the skin through needle bores. (Adapted from 
[10,19]) 
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Zosano Pharma (Fremont, US) developed the Macroflux® delivery system composed 
of titanium needles that can be coated with diverse drugs and vaccines [41,42]. This 
MN modification is restricted by the amount of protein/drug that can be coated onto 
the microneedles. Furthermore, parameters of the coating formulation such as 
viscosity and surface tension should be determined carefully to avoid on the one 
hand protein aggregation and to facilitate on the other hand an adhesion to the 
needle surface [43].  
Another possibility to modify the type of solid MNs is the use of soluble needle 
materials (Figure 4, C). So-called dissolving MNs include an encapsulated API and 
have been fabricated primarily from polymers which are biocompatible, 
biodegradable and exhibit an established safety profile in medical tools [44]. 
Examples of materials that might be processed are polylactic acid, polyglycolic acid 
and carbohydrates (sugars, carboxymethyl cellulose) [44,45]. Depending on the 
chosen material the needles can be utilised for prolonged release of the drug. Similar 
to the coated MNs the use of dissolving MNs is limited to a maximum of incorporated 
API as well. Increasing the drug load might in turn compromise the mechanical 
strength of the needles. A critical point in case of incorporating thermosensitive 
drugs, e.g. proteins, might be the manufacturing process which might involve high 
temperatures (> 60 °C) necessary for melting the sugars or polymers [46,47].  
Infusion of liquid drug formulations is a promising feature in the MN technology and 
presented in Figure 4, D [19]. Hollow MNs containing bores that offer the possibility 
of transporting API solutions through the needles by diffusion or by a pressure-driven 
flow. They facilitate the transport of higher amounts of drug compared to coated or 
soluble MNs. However, the volume of formulation that can be infused is limited by the 
back pressure from the densely packed layers of skin [48]. Tuan-Mahmood et al. 
(2013) emphasised that most studies using hollow MNs have been focused on their 
fabrication aspects and less on their potential in delivering compounds across the 
skin. The transdermal delivery of insulin into diabetic rats might be one promising 
example for the use of hollow MNs [49].  
In general, MNs have a good patient compliance because there are less painful 
compared to hypodermic needles. Due to their small size, MNs are less likely to 
reach nerve endings in the dermis that perceive pain [19]. A frequently discussed 
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safety consideration regarding the puncturing of skin is the possibility that 
microorganism could gain access and potentially lead to infections. Channels created 
by hypodermic needles were reported to induce greater microbial penetration than 
those by MNs. Donnelly et al. (2009) emphasised the need for more exhaustive 
in vivo studies to conclusively demonstrate the low infection risk of MNs [50]. 
Additional approaches to enhance patient safety will be established by sterile or 
aseptic manufacture and by fabricating MNs from dissolving or biodegradable 
materials to prevent reuse [50]. 
This technology serves as an important and exciting advance in dermal and 
transdermal delivery techniques. The delivery of a broad range of molecules from 
small molecular weight drugs to large hydrophilic biopharmaceuticals such as 
vaccines and proteins is possible. MN devices are potential drug delivery systems 
that have been made by many pharmaceutical companies to line up their product 
portfolio as better options instead of an existing delivery systems. MN based systems 
like Soluvia™ by BD or Fluzon Intradermal® by Sanofi Pasteur received FDA 
clearance for the delivery of influenza vaccination [19]. There are still more products 
on the market, in clinical trials or under development. The shape and design of MN 
devices are versatile just as their field of application, underlining the potential as 
dermal/transdermal delivery systems.  
 
2.2 Protein Stability 
Protein stability is a particularly relevant issue in the pharmaceutical field and will 
continue to gain more importance as the number of therapeutic protein products 
increases. Proteins are large biomolecules of a complex architecture. They consist of 
one or more polypeptide chains from the serial condensation of various amino acid 
monomers. Amino acids are covalently bonded together in chains by peptide bonds 
between the amino nitrogen and the carboxyl carbon. Sequences with fewer than 
20 amino acids are generally referred to as peptides, while the term polypeptide or 
protein is used for longer chains [51].  
There are four levels of protein structure, namely primary, secondary, tertiary and 
quaternary. The primary structure describes the linear arranged amino acids in a 
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polypeptide chain. The secondary structure includes the folding of polypeptide chains 
into huge substructures. The structural conformation of secondary structure depends 
on the formation of hydrogen bonds and leads to the two main substructures, α-helix, 
and the β-sheet. Tertiary structure of protein is its native or functional 3D-structure. 
Many stabilising forces fashion the 3D-shape of a protein such as hydrophobic 
interactions, disulphide bridges, hydrogen bonds, and Van der Waals forces. These 
interactions are weak, short range and sensitive to external influences as pressure, 
temperature, pH and ionic strength [51].  
Some proteins are made up of multiple polypeptide chains, often referred to as 
subunits. These protein subunits interact with each other (via hydrogen bonds, 
disulphide bridges, salt bridges etc.) and arrange themselves to form a larger 
aggregate protein complex termed as quaternary structure [52].  
In living organism proteins act as transporter for ions and other molecules regulating 
most chemical reactions. Proteins that can catalyse biological reactions are called 
protein enzymes. Enzymes have a high specificity to the reaction they catalyse. This 
might be one property that makes them so important as diagnostic and research 
tools [52,53].  
A protein´s structure is directly related to its function, thus anything that severely 
disrupts the natural structure will also disrupt the function or activity. Many proteins 
are structurally unstable especially in solution and are susceptible to conformational 
changes during manufacturing, storage, handling steps or shipping. Instabilities can 
be divided into chemical or physical instabilities and are mostly concomitant acting in 
a synergistic way, e.g. an oxidation or deamidation can increase the sensitivity to 
aggregation [53,54].  
2.2.1 Chemical Instability 
Chemical degradation involves processes that create or break covalent bonds. 
Chemical modifications of a protein include reactions, such as oxidation, reduction, 
deamidation and hydrolysis [53]. 
Deamidation is one of the most common chemical degradation pathway of proteins 
and peptides which particularly involves the hydrolysis of side chain amides 
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asparagine and glutamine [54]. Generated degradation products can lead to 
impurities and increase the immunogenicity, while they likewise decrease the 
bioactivity, e.g. the deamidation of peptide growth-hormone-releasing factor caused a 
500-fold inactivation. Possibilities to reduce the deamidation rate in a solution might 
be the optimisation of the pH (generally minimised at pH 3-5) and the decrease of 
dielectric strength (addition of organic solvents). Furthermore, in lyophilised 
formulations the deamidation is reduced, because of the absence of free water where 
the reaction can occur [55]. 
Another primary chemical degradation process of proteins and peptides is the 
oxidation. Proteins that contain methionine, cysteine, histidine, tryptophan or tyrosine 
are particularly at risk to get damaged by reactive oxygen species [54]. The oxidation 
can alter the physicochemical characteristics of proteins like folding, subunit 
association and leads to physical instabilities (fragmentation or aggregation). There 
are several methods to minimise the oxidative degradation e.g. to control the 
enhancing factors (pH, temperature, light exposure, buffer conditions etc.) or to add 
antioxidants (ascorbic acid) and metal chelating agents (EDTA) to the protein 
formulation [54]. 
2.2.2 Physical Instability 
Physical degradation includes protein unfolding, surface adsorption, aggregation and 
precipitation. Protein aggregation is the most common physical instability because it 
is encountered routinely during manufacturing, processing, storage, and shipping. 
For protein therapeutics, the presence of aggregates is undesirable as they may lead 
to an immunogenic reaction and decrease of bioactivity [56]. The impact of 
aggregation depends on the physicochemical attributes of each protein relative to its 
functional domains and natural activity. Enzymes such as catalase and urease can 
lose up to 50 % of their activity just after shaking due to the mechanical stress [55]. 
Protein aggregation is often irreversible and accompanied by large changes of 
secondary as well as tertiary structure which result in the loss of native structure. 
Physical degradation processes can influence each other. External stress including 
temperature, pH, removal of water, high shear and the presence of metal ions can 
lead to an irreversible disruption of native state of a protein and finally cause a 
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denaturation or unfolding. Partially unfolded protein molecules are especially prone to 
aggregation [53,57]. 
In general, protein formulations, e.g. in a dissolved state, can be stabilised against 
physical destabilisations by optimising the pH, ionic strength, adding sugars, amino 
acids and/or surfactants [55]. In many cases, nonionic surfactants such as 
Polysorbate 20 and Polysorbate 80 can prevent the formation of aggregates if used 
in concentrations below the critical micelle concentrations. Via a protein-surfactant 
interaction these compounds stabilise proteins by lowering the surface tension and 
binding to their hydrophobic sites, reducing the possibility of protein-protein 
interactions, which could lead to aggregations, too [58]. 
There are several more techniques to improve the stability of proteins in solid or 
dissolved state. The choice of the "right" mechanism depends on the requirements of 
the formulation and the nature of protein.  
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Surfactants 
1.1.1.1 Natural Surfactants 
The group of natural surfactants is not univocally defined. Surfactants taken directly 
from a natural source as well as those synthesised from natural raw materials like 
sugars, sterols or amino acids are usually categorised as “natural”. Holmberg et al. 
(2001) emphasised that lecithin obtained from a natural source (either soybean or 
egg yolk) is probably the best example of a truly natural surfactant [59]. This project 
focused on the use of lecithins because of their versatile applications (drug and food 
industry) as well as their property to be well-tolerated on skin (approved as 
penetration enhancer and surfactant) [60]. 
The U.S. Pharmacopeia defines lecithins as a “complex mixture of acetone-insoluble 
phosphatides, which consists chiefly of phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylinositol, and phosphatic acid, present in 
conjunction with various amounts of other substances such as triglycerides, fatty 
acids, and carbohydrates (...)” [61]. Typical for natural phospholipids is the 
composition of fatty acids with a polar head group (schematic representation in 
Figure 5, B). Lecithins are also determined by the composition of the natural starting 
material and the applied purification. Moreover, the chemical composition determines 
the properties and their application field.  
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Figure 5. General lecithin structure. (A) shows a part of monoacyl phosphatidylcholine (MAPL), which 
is linked to one fatty acid chain (R = H) compared to diacyl phosphatidylcholine (DAPL; R = fatty acid). 
(B) shows a simplified model of lecithins (left) next to their arrangement in biological membranes 
(right). 
Next to the simplified lecithin structure in Figure 5, B section A shows a part of 
monoacyl phosphatidylcholine (MAPL). This thesis focused on phospholipids with a 
higher content of MAPL besides the diacyl phosphatidylcholine (DAPL) content in the 
formulation development. As shown in Figure 5, A MAPL is linked to only one fatty 
acid chain (R = H) compared to DAPL (R = fatty acid). Hence, MAPL has a higher 
polarity. The higher the polarity, the higher is the self-emulsification power [62]. In 
present investigations, Lipoid S LPC 80 (Lip80, Lipoid GmbH, Ludwigshafen, 
Germany) was applied as hydrophilic representative of a phospholipid containing 
80 % of MAPL.  
As endogenous substances phospholipids are structural and functional components 
of all cell membranes (Figure 5, B). This might be the reason for their good 
tolerability, and the drug penetration enhancing effect on skin making phospholipids a 
popular group of emulsifying ingredients. 
1.1.1.2 PEGylated Surfactants 
The abbreviation PEG stands for polyethylene glycol which is an important structural 
part of many nonionic surfactants. In more detail, the term PEGylated means the 
covalent coupling of a PEG structure to another large molecule. Such a molecule 
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could be a therapeutic protein or, as in this study, a hydrophobic molecule to produce 
non-ionic surfactants [63]. Polyoxyl castor oil (USP/NF Polyoxyl 15 castor oil) and 
polyoxyethylene-20-sorbitan monooleate (USP/NF Polysorbate 80) are two 
representatives of the huge family of nonionic surfactants and of importance in the 
following experiments.  
Polyoxyl 15 castor oil, also known under the trade name Kolliphor® EL (BASF SE, 
Ludwigshafen, Germany), is an oil-in-water emulsifier or solubiliser with a hydrophilic-
lipophilic balance (HLB) value between 12 and 14. Kolliphor® EL is used in many 
different branches of industry. It is particular suitable as solubiliser in liquid fat-soluble 
vitamin solutions or hydrophobic active pharmaceutical ingredients [64].  
Polysorbate 80 (Caesar & Loretz GmbH, Hilden, Germany) is reported as a very 
common non-ionic oil-in-water surfactant [65]. Because of its high HLB value of 16.0 
it is suitable as a solubiliser for poor water-soluble drug substances in either liquid or 
solid dosage forms. Furthermore, Polysorbate 80 is a popular emulsifier or 
coemulsifier in pharmaceutical preparations like semisolids and foams [66]. 
Kolliphor® EL and Polysorbate 80 are promising surfactants for dermal formulation 
systems due to their versatile application fields and good skin tolerance [64,66].  
3.1.2 Lipophilic Ingredients 
In the present study, several lipid excipients from the portfolio of Gattefossé (Saint-
Priest, France) were selected. Plurol Oleique® CC 497 (USP/NF Polyglyceryl-3 
dioleate), Labrafac™ PG (USP/NF Propylene glycol dicaprylocaprate), Labrafac™ 
Lipophile WL 1349 (USP/NF Medium chain triglycerides), Peceol™ (USP/NF Glyceryl 
monooleate, Type 40) and Maisine™ 35-1 (USP/NF Glyceryl monolinoleate) are 
known examples and were utilised in the following experiments [67].  
Plurol Oleique® CC 497 (PO CC 497) is classified as water-in-oil surfactant with an 
HLB value of 6. It is a viscous lipophilic liquid that improves the stability of emulsions 
as well as the solubility of drugs [68].  
Labrafac™ PG, Labrafac™ Lipophile WL 1349, Peceol™ and Maisine™ 35-1 are 
defined as oily vehicles. In general, they are used as oily phase for topical 
formulations, but can also solubilise lipophilic active pharmaceutical ingredients 
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(APIs). Essential for this property is their surface activity with HLB values of 2 
(Labrafac™ PG) and 1 (Labrafac™ Lipophile WL 1349, Peceol™ and Maisine™ 35-
1), respectively [69–71]. 
To sum up, all these lipid excipients are high performance liquid solubilisers that can 
be used to improve the drug delivery in a variety of formulations (oral, topical and 
partly parenteral). In addition, they are characterised by a good tolerability especially 
on human skin [72–74]. 
3.1.3 Catalase 
Catalase is an ubiquitous existing globular protein that can be found in almost all 
aerobic and anaerobic organisms, such as mammalians, plants or bacteria. It is an 
antioxidative enzyme which decomposes hydrogen peroxide into water and oxygen. 
Therefore, it plays an important role in protecting cells against reactive oxygen 
species [75].  
Within this study, a lyophilised catalase from bovine liver (Sigma Aldrich, St. Louis, 
MO, US) with an activity of 2000-5000 U/mg was used. Bovine liver catalase is a 
tetramer (240 kDa) composed of four identical tetrahedrally arranged subunits 
(Figure 6). Each 60 kDa subunit contains a haeme group and NADPH in its own 
active side [76,77]. The secondary structure of catalase is composed of two globular 
domains (β-barrel and α-helical domain). The β-barrel is anti-parallel eight-stranded 
and includes at least six inserted α-helices in the central area, as indicated in Figure 
6 [78]. 
All haeme-containing catalases perform the degradation of hydrogen peroxide in a 
two-stage catalytic mechanism. First, a molecule of hydrogen peroxide binds and 
oxidises the haeme to an oxyferryl species. A porphyrin cation radical is generated 
when one oxidation equivalent is removed from iron and, generally, one from the 
porphyrin ring. Then, a second hydrogen peroxide molecule binds and acts as 
reducing agent to regenerate the resting state enzyme, with the concomitant 
production of oxygen and water [78,79]. 
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Figure 6. Crystal structure of bovine liver catalase without NADPH. The tetrameric structure is well 
defined by the differently coloured four subunits. (Adapted from [80]) 
Bovine liver catalase is insoluble near its isolelectric point of pH 5.4, and soluble 
outside this pH range. It is most stable in a 50 mM phosphate buffered saline (PBS) 
at pH 7.0. Below a pH value of four or higher than a pH of nine the three-dimensional 
structure changes and the enzymatic activity is considerably inhibited [81,82].  
3.1.4 Microneedle Devices 
Microneedling is a minimal invasive treatment of skin texture. It is already established 
in cosmetic and medical applications to tighten or improve skin texture as well as in 
scar therapy [83]. Three commercially available needle devices Dermaroller®, 
eDermastamp® and Dermastamp® (Dermaroller GmbH, Wolfenbüttel, Germany) were 
examined.  
The different design of applied needle devices is shown in Figure 7 and results in a 
deviating handling of piercing process.  
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Figure 7. Overview of the three evaluated needle devices. The image (A) shows Dermastamp®, (B) 
Dermaroller® MC405 and (C) the electrically driven eDermastamp®. Each device has the same 
conically shaped needles, used with 500 µm needle length. 
However, the three devices have the same conically shaped needles, made of 
stainless steel. In the current study, uniform needle dimensions were used (500 µm 
in height, 350 µm diameter at the base and 84 µm at the tip) [84]. Further technical 
data are summarised in Table 1. 
Table 1. Summary of technical information of three applied needle devices. 
 
3.1.5 Full-Thickness Human Skin Models 
The term "full-thickness human skin model" means a reconstructed skin equivalent 
engineered in a tissue culture insert. Full skin equivalents consist of human 
keratinocyte cultures grown on fibroblasts containing collagen matrices with an 
underlying microporous membrane ensuring contact to the cell culture media [26].  
Model 
Available needle 
length 
Number and 
arrangement of 
microneedles 
Application 
Dermaroller® MC405 fixed 72 needles, rows rolling process 
eDermastamp® 
variable, adjustable by 
user (0-1.5 mm) 
6 needles, rows 
automatically 
driven, 
50-150 pricks/min 
Dermastamp® fixed 6 needles, radial  stamping process 
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To date three commercially available reconstructed human skin models are on the 
market: EpiDerm™ FT (MatTek Corporation, Ashland, US), AST2000-FT 
(CellSystems Biotechnologie Vertrieb GmbH, Troisdorf, Germany) as well as 
Phenion®-FT (Henkel AG & Co. KGaA, Düsseldorf, Germany). These skin models 
are promising tools in versatile research topics. Furthermore, they are used by 
pharmaceutical, chemical and consumer product companies for a broad range of 
applications such as skin corrosion, -irritation and sensitisation tests are only a few 
examples [85].  
EpiDerm™-models are most often cited, hence the user benefits from extensive 
experience. Therefore, in this thesis EpiDerm™ FT 400 from MatTek Corporation 
(Ashland, US) was utilised for the performances of tolerability studies. The presence 
of fibroblast-keratinocyte cell interactions is necessary for the release of inflammatory 
biomarkers like secondary cytokines. Epiderm™ FT consists of organised basal, 
spinous, granular and cornified epidermal layers analogous to those found in vivo 
[86]. An example of the skin histology of the chosen model is shown in Figure 8.  
 
Figure 8: Microscopic image of skin histology samples of Epiderm™ FT representing the epidermis 
containing basal, spinous as well as granular keratinocytes and stratum corneum. The underlying, 
dermis contains numerous viable fibroblasts and is displayed brightly (H & E staining,  
400x magnification). Reprinted with permission of MatTek Corporation [87]. 
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The reconstructed full-thickness skin tissues have a surface area of 1 cm² with a total 
thickness of 700 µm and are shipped as transwell system in 6-well plate units [88]. 
Surface area and thickness of EpiDerm™ FT 400 match the intended needle 
application. 
All tissues need constant contact to culture media based on Dulbecco`s Modified 
Eagle`s Medium supplemented with growth factors, antibiotics, anti-fungal agents 
and other additives (EFT-400-MM, MatTek Corporation, Ashland, US). Skin tissues 
are screened and tested negative for pathogens such as HIV and hepatitis B. It is 
necessary to handle this biological material under aseptic conditions in a laminar flow 
hood [89]. 
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3.2 Methods 
3.2.1 Multiple Light Scattering 
Multiple light scattering (MLS) is the underlying technology of Turbiscan LABTM 
(Formulaction SAS, L`Union, France), which was utilised in the current experiments. 
The Turbiscan LABTM allows the physical properties analysis of emulsions or 
suspensions, especially size measurements, detection of concentration variations, 
and changes in physical properties such as sedimentation, creaming as well as 
flocculation or coalescence.  
The measurement is performed by sending a light beam (λ = 880 nm) through a 
cylindrical glass cell containing the liquid sample. Two synchronous optical sensors, 
detect the transmitted or backscattered light. The transmission detector receives the 
light going through the sample (at 180° from the incident light beam), whereas the 
backscattering detector receives the light scattered backwards by the sample (at 45° 
from the incident light beam). Transmission and backscattering values directly 
depend on the particle diameter and their volume fraction [90].  
Based on recommendations of the manufacturer this study was focused on the 
detection of transmission values enabling the differentiation between clear and turbid 
dispersions, however, backscattering is suggested for the analysis of more opaque 
and concentrated systems [90].  
Figure 9 shows the chosen experimental setup for the Turbiscan LABTM. Samples 
were filled in a cylindrical glass vial and equilibrated at 25 °C for 30 min.  
After the equilibration time, variations in optical transparency were measured over 
time (Figure 9). First, a fixed transmission value in % was recorded at a fixed height 
of 15 mm directly after the preparation. Second, cumulative transmission curves were 
taken, indicating time-dependent stability changes of formulations with one 
measurement per hour over 24 h. For the detection of time-dependent variations the 
laser evenly scanned the glass vessel along 20 mm height (Figure 9). 
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Figure 9. Setup of Turbiscan LABTM with a typical cylindrical sample vessel. The optical transparency 
of each formulation was controlled via transmission values in %, at 25 °C. Transmission values were 
taken at a fixed height of 15 mm or scanned along 20 mm. (Adapted from [90]) 
3.2.2 Dynamic Light Scattering 
Information about the inner structure of developed colloidal formulations were 
determined with dynamic light scattering (DLS). DLS, also known as photon 
correlation spectroscopy, measures changes in light scatter intensity over time due to 
Brownian motion of molecules or particles in dispersion [91]. Particles are constantly 
moving based on their random collision with fast-moving molecules of the liquid 
surrounding (Brownian motion) [91]. An essential factor of this phenomenon for DLS 
is that small particles move faster than large particles. In case of illumination of a 
sample via laser (λ = 633 nm) the intensity of scattered light (detected at an angle of 
173°) from small particles will fluctuate quicker than for larger particles showing 
slower fluctuations The relationship between the size and the speed of a particle due 
to Brownian motion is defined in the Stokes-Einstein equation (1) [92]. 
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D = 
k × T
6 × π × η × rh
 (1) 
D = diffusion coefficient 
k = Boltzmann constant 
T = absolute temperature 
η = dynamic viscosity 
rh = hydrodynamic radius 
The fluctuation of scattering intensity is detected over time intervals, plotted as 
correlation curves, and is used to extract information about the diffusion coefficient of 
particles or droplets in a solution. Based on the measured diffusion coefficient the 
hydrodynamic radius of the particles or droplets can be calculated using Stokes-
Einstein equation (1) (in the present study given as z-average). The size distribution 
generated by DLS is an intensity distribution, not a number or a volume distribution, 
because it is calculated from the signal intensity [92].  
In the present study, DLS measurements were performed using the Zetasizer 
Nano ZS (Malvern Instruments, Worcestershire, UK). Nano ZS series can be used for 
the detection of particle sizes between 0.3 nm to 10 µm as maxima. The most 
important and reliable values produced by this technique are the z-average diameter 
and the polydispersity index (PDI). Both parameters were used for the 
characterisation of developed formulations. The z-average also known as "cumulants 
mean" is the mean hydrodynamic diameter calculated from signal intensity, whereas 
the PDI describes the width of cumulants analysis giving values between zero and 
one. Calculations for both parameters are defined in the ISO 13321:1996 E and 
22412 [92]. All DLS measurements were performed with undiluted, particle free 
filtered (cellulose acetate membrane, 0.2 µm pore size) samples. 
3.2.3 Advanced Differential Scanning Fluorimetry (nanoDSF) 
nanoDSF is an advanced Differential Scanning Fluorimetry method measuring the 
intrinsic fluorescence of proteins containing aromatic amino acids like tryptophan. 
The measurable fluorescence of tryptophan strongly depends on its position in the 
protein and the closed surrounding. Because of its hydrophobic character it is usually 
located in the hydrophobic core of proteins isolated from the surrounding hydrophilic 
solvent [93]. Intrinsic protein fluorescence can mainly be attributed to the 
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fluorescence of tryptophan. The fluorescence of tryptophan is excited at 280 nm and 
emitted at 330 nm in non-polar environment and 350 nm in polar environment [94]. 
The measuring principle of nanoDSF is an increasing temperature profile followed by 
changes in the intrinsic fluorescence of a protein. Figure 10, (A) depicts the process 
of protein unfolding upon heating steps. Therefore, changes of tryptophan 
fluorescence at 350 nm and 330 nm wavelength can be monitored and used to 
determine the unfolding transition temperature Tm (°C). Tm is defined as temperature 
at which half of the protein is unfolded and acts as important parameter for the 
conformational stability of a protein [95].  
 
Figure 10. Measuring principle of nanoDSF. Increasing temperature causes protein unfolding and 
changes in tryptophan fluorescence (A). The transition from folded to unfolded status of a protein is 
plotted as ratio of two wavelengths 350 nm and 330 nm against increasing temperature (B, black line) 
next to its first derivative (blue line). (Adapted from [95,96]) 
The data at emission wavelengths of 350 nm and 330 nm are plotted as ratio (Figure 
10, B black line) against the temperature. Additionally, their first derivative was 
calculated, displaying as peak at the point of maximal slope, which corresponds to Tm 
(Figure 10, B blue line). Destabilising chemical or thermal influences might lead to 
changes in a protein and hence to changes in fluorescence intensities as well as 
shifts in Tm [93]. 
In most cases the loss of protein stability correlates with a reversible or irreversible 
unfolding often followed by an aggregation process. nanoDSF technology also 
enables the determination of aggregation behaviour (colloidal stability) of proteins via 
backreflection optics. Protein aggregates scatter the incident light similar to particles 
and the intensity of reflections is quantified by a detector [97].  
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In the present study nanoDSF measurements were performed with Prometheus 
NT.48 in laboratories of nanoTemper technologies GmbH in Munich. For the 
measurement 10 µL of each lipophilic protein formulation were loaded undiluted into 
standard treated Prometheus NT.48 capillaries and subjected to a thermal ramp from 
20 °C to 95 °C at a heating rate of 1 °C/min. A closer look at the described technical 
setup is shown in Figure 11.  
 
Figure 11. Technical setup of Prometheus NT.48. The lipophilic protein formulation is heated in 
capillaries with a thermal gradient from 20 °C to 95 °C. The protein is excited by a LED laser (280 nm) 
and changes of intrinsic tryptophan fluorescence emission are detected [98]. (Adapted from [95]) 
3.2.4 Size Exclusion Chromatography 
Size exclusion chromatography (SEC) is a liquid column chromatographic technique 
that separates biomolecules according to their molecular weight or hydrodynamic 
volume. The stationary phase consists of porous particles with a defined pore size 
through which the molecules diffuse based on their molecular weight and 
hydrodynamic volume (Figure 12) [99].  
Basically, SEC works by trapping small molecules in the porous material of the 
stationary phase resulting in a larger accessible volume and a longer retention time. 
Hence, larger molecules will pass the column material faster and elute first.  
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SEC separates on the basis of enthalpic interactions with a stationary phase, in 
contrast to other liquid chromatography separation techniques. In liquid 
chromatography generally used secondary interactions like adsorption partition or ion 
exchange are in SEC unwanted and must be avoided [99,100]. Figure 12 presents 
an overview of described SEC setup. 
 
Figure 12. SEC separation technique. Small molecules can freely diffuse into and on porous packaged 
stationary phase, thus they elute at a later time. Molecules which are too large to penetrate the pores 
elute earlier. 
In the present study an aqueous 50 mM phosphate buffered saline pH 7.0 modified 
with 200 mM L-arginine hydrochloride (Arg-HCl, Appendix chapter 8.1.2) was used 
as isocratic mobile phase. As typical for an aqueous SEC a silica-based stationary 
phase packaging was used [101]. The applied 5 µm PSS PROTEEMA analytical 
300 Å (8 x 300 mm) SEC column (PSS Polymer Standards Service GmbH, Mainz, 
Germany) consisted of a special modified silica and is well-suited for a separation 
range between 10-1200 kDa. All experiments were performed with a Merck-Hitachi D 
7000 system (Merck-Hitachi, Darmstadt, Germany) coupled to a UV detector at 
280 nm.  
SEC is frequently used for analysis and quality control of proteins, studying their 
aggregation or degradation products [102]. This study focused on the detection of 
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changes in protein stability within the formulations as an important quality parameter 
next to the investigations with nanoDSF (chapter 3.2.3).  
Protein formulations were diluted with mobile phase to get a concentration of 
approximately 1 mg/mL. Sample volumes of 50 µL were injected as triplicate into 
SEC and run at a flow rate of 0.7 mL/min (Appendix, chapter 8.2).  
3.2.5 Catalase Activity Assay 
The catalase activity was examined with a method modified after Beers and Sizer 
(1952) utilising the ability of an active enzyme to degrade hydrogen peroxide (H2O2) 
to water and oxygen. One unit of catalase can decompose one micromole of H2O2 
per minute at pH 7.0 and 25 °C.  
Figure 13 shows the rate of H2O2 decomposition which can be measured by the 
decrease in absorption at a wavelength of 240 nm over time. In the current study the 
measurements were performed with a Varian Cary® 50 UV-Vis Spectrophotometer 
(Agilent Technologies, Santa Clara, US) enabling one absorbance reading per 
second over a time range of 180 seconds [103]. 
 
Figure 13. Typical degradation curve of H2O2. Catalase is catalysing the decomposition of H2O2 to 
water and oxygen. The disappearance of H2O2 can be measured as function of absorbance at 240 nm 
against time. Red dotted lines label the area of linearity between absorbance and time which are 
crucial for the activity calculations. 
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Lipophilic samples, containing 1 % (m/V) catalase, were diluted just before use to 
approximately 100 U/mL in 50 mM potassium phosphate buffer pH 7.0 at 25 °C. 
100 µL of sample solution were mixed with 2900 µL of a 0.045 % (V/V) H2O2 solution 
in a cuvette. The degradation reaction was monitored for 180 seconds as 
ΔA240/second. To calculate the enzyme activity of catalase in U/mg the decrease of 
time in the linear range between 0.45 to 0.40 (red dotted line in Figure 13) was 
determined and used in the following equations (2) and (3) [103]: 
 
U mL enzyme⁄ = 
3.45 × df 
time × 0.1 
 (2) 
 
 
U mg solid = 
U mL enzyme⁄
mg enzyme mL formulation ⁄
 ⁄  (3) 
df = dilution factor 
time = minutes, required for A240 to decrease from 0.45 to 0.40 
3.2.6 Skin Preparation Techniques 
Human, abdominal, female skin (42 years) obtained after a plastic surgery (Dr. med. 
A. Häring, esthesis-Kiel, Kiel, Germany) was used in subsequent analyses. Patients’ 
identities were kept anonymous and they were informed about the experimental use.  
For later skin preparations it was necessary to completely remove the fat tissue and 
to clean the surface with PBS pH 7.4 (Dulbeccos Phosphate Buffered Saline without 
CaCl2 and MgCl2, Sigma Aldrich, St. Louis, US). Afterwards, the skin was dried with a 
cotton swap, cut into 5 x 5 cm pieces at least and wrapped into aluminium foil. Stored 
at -30 °C skin is stable with regard to its barrier function for up to six month [104].  
1.1.1.3 Heat-Separation of Epidermis Sheets for Scanning Electron Microscopy 
studies 
Heat-separation is a simple and fast technique to obtain pure epidermal sheets. 
Generally, the epidermal layers are used as barrier in permeation studies with Franz 
diffusion cells, however, in the current study they were utilised for microneedle device 
characterisation experiments [104].  
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The cadaver skin pieces were thawed at room temperature and carefully fixed 
between two aluminium plates. Heating the fixed full-thickness skin at 60 °C in 
purified water for 120 s resulted in a clear separation of the epidermis from the 
dermis. With blunt forceps the epidermis was carefully peeled off from the underlying 
dermis and hydrated in PBS pH 7.4 for 30 min. The hydration step ensures a 
complete unfolding of the epidermis.  
Afterwards, the epidermis sheet was ready for perforation steps with a microneedle 
device (chapter 3.1.4). To visualise formed micro channels on skin surface, scanning 
electron microscopy (SEM) was utilised. 
For this purpose the perforated sheet was fixed with a 4 % (m/m) buffered formalin 
solution overnight. After at least 16 h the sample was rinsed with purified water and 
dehydrated in alcoholic solutions with increasing ethanol content every 30 min 
(50 %, 70 %, 96 %, 99 %, V/V) [104]. The membrane was mounted on an aluminium 
sample holder (Plano GmbH, Wetzlar, Germany) with a special glue of conducting 
carbon particles (Plano Leit-C nach Göcke, Plano GmbH, Wetzlar, Germany) and 
sputter coated using a SCP 005 Sputter Coater (BAL-TEC AG, Balzers, 
Liechtenstein). Finally, the coated sample was transferred into the SEM chamber and 
imaged with an acceleration voltage of 2 kV. Skin surface images were measured 
with a SE-2 detector as part of the Zeiss Ultra 55 Plus SEM (Carl Zeiss NTS GmbH, 
Oberkochen, Germany) setup. 
1.1.1.4 Paraffin Embedding and Sectioning 
In this procedure, tissue is dehydrated through a series of graded ethanol baths to 
displace the water, and then infiltrated with liquid paraffin wax. The infiltrated tissues 
are then embedded into wax blocks. Once the tissue is embedded it is stable for 
many years [105]. 
The present study used for the dehydration step of fresh skin samples an 
automatically controlled Leica ASP300 Tissue Processor (Leica Mikrosysteme 
GmbH, Wetzlar, Germany). Finished samples were embedded in paraffin and 
manually sectioned into 5 µm slices with a Microm HM355 microtome (Thermo Fisher 
Scientific GmbH, Schwerte, Germany).  
MATERIALS AND METHODS 
36 
 
Most cells are colourless and transparent, therefore, the sections were stained with a 
non-specific, commonly used staining system called H & E (Haemotoxylin and 
Eosin). The basic principle is a colouring of acidic (with Haematoxylin) next to basic 
(with Eosin) components in cells which results in characteristic pink and purple 
images [105].  
Advantages of H & E staining combined with paraffin sections are high contrast 
images going along with long storage stability. However, detrimental effects are the 
high number of alternating dehydration and incubation steps which may lead to a 
swelling of skin layers, thus changing the tissue structure.  
With regard to the evaluation of tolerability studies with human skin models, this 
preparation technique was an essential part of histological studies. The assessment 
for pathohistological changes was performed in cooperation with the group of 
Professor E. Proksch at the Department of Dermatology, Kiel University.  
1.1.1.5 Cryo-Embedding and -Sectioning 
Cryosections are rapidly and easily performed prior to paraffin fixation. They provide 
overview images as a snapshot of cell status, without tissue changes that might 
occur as consequence of various incubation steps. Therefore, this procedure was 
applied in the present study for visualisation of microchannels as cross section in 
cadaver as well as in EFT-400 skin samples.  
Freshly pierced human skin samples were placed in a microcentrifuge tube and 
frozen in liquid nitrogen. It is necessary to pay attention on rapid freezing procedures 
to reduce ice crystal formation as well as morphological damages. Frozen samples 
were embedded in a freezing medium (Tissue-Tek, Sakura Finetek, Torrance, US) 
on metal sample stubs (Figure 14, A).  
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Figure 14. Setup of CryoStar NX 70. Image (A) shows yellow, red and blue coloured sample stubs 
used for tissue embedding. (B) Presents a detailed view on the chuck holding the stub with a complete 
embedded, frozen sample. The arrow marks the anti-roll plate for tissue slices and the subjacent knife-
holder. 
Afterwards the stub was fixed on a chuck, as shown in Figure 14, B, and cut in 5 µm 
thick slices in a cryostat (CryoStar NX 70, Thermo Fisher Scientific GmbH, Schwerte, 
Germany) at -20 °C. For the following microscopic examination skin slices were 
transferred on a microscope slide and analysed with an Axioskop 40 light microscope 
(Carl Zeiss Microscopy, Oberkochen, Germany). Without further fixation steps the 
skin slices are stable for 24 h [106].  
3.2.7 Transepidermal Water Loss Measurements 
Measurements of transepidermal water loss (TEWL) detect the water evaporation 
from the skin as an important parameter for the evaluation of skin water barrier 
function. Already slight damages of outermost skin layers disturb the natural water 
homeostasis and increase the water loss [107].  
TEWL is typically used to evaluate in vivo effectiveness and/or tolerability of several 
dermal formulations [108]. In the present study, this technique was used to 
characterise the efficiency of three needle devices to form microchannels into in vitro 
cadaver skin samples. Contrary to clinical tolerability evaluations, that usually aim a 
low water loss, in the current investigations an increased TEWL was intended. 
For the assessment of the TEWL the Tewameter® TM 300 (Courage+Khazaka 
electronic GmbH, Cologne, Germany) was applied (Figure 15).  
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Figure 15. Schematic drawing of Tewameter® TM 300 probe. The Tewameter® probe is a hollow, 
cylindrically formed open chamber with two pairs of sensors (temperature and relative humidity). 
(Adapted from [108]) 
The Tewameter® probe measures the density gradient of the water evaporation from 
the skin indirectly by two pairs of sensors (temperature and relative humidity) located 
in a hollow cylinder (schematically shown in Figure 15). A microprocessor analyses 
the results and expresses them as evaporation rate in g/h/m2.  
The hollow, open cylinder facilitates the expansion of a homogenous diffusion zone 
above the skin surface and thus allows continuous TEWL measurements without any 
influences of the microclimate of the skin. Nevertheless, the so-called "open chamber 
method" is exposed to interfering influences like air temperature, ambient relative 
humidity (rH), and anatomical sites. To ensure a high accuracy all TEWL analyses 
were performed on the same day, at 22 °C and 33 % rH.  
To avoid unnecessary dehydration of skin, thawed samples were removed from the 
aluminium foil directly before measurements were performed. The probe was placed 
on the skin surface in a fixed position. Continuous detections of TEWL values were 
started and stopped automatically after reaching a constant standard deviation of 
< 0.2 g/h/m2 [107]. 
3.2.8 Tolerability Studies with a Full-Thickness Human Skin Model 
Upon arrival of EFT-400 tissues, the inserts were placed in fresh 6-well plates, fed 
with 2.5 mL of culture media (EFT-400-ASY, MatTek Corporation, Ashland, US) and 
equilibrated at 37 °C; 5 % CO2. Following 16-18 h pre-incubation, the culture medium 
was replaced with fresh medium. Tissues were now ready within 24 h for the 
experiment [109].  
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60 µL of liquid sample volume were dispensed and gently spread atop the tissue 
surface using a pipette (Figure 16, A). In case of a perforation with Dermastamp® 
500 µm, the tissue inserts were taken out of the well plate and pierced 10-fold evenly 
through the surface (Figure 16, B). 
 
Figure 16. Treatment of EpiDerm™ FT 400. The application of liquid samples using a pipette is shown 
in image A. In case of a perforation with Dermastamp® 500 µm, the tissues were pierced outside their 
well plate (B). 
According to the experience of Badran et al., this study utilised the most effective 
application order; first piercing followed by applying the test formulation [104]. Each 
skin treatment was performed in triplicate.  
After 3, 8 and 24 h culture medium was collected for analysis and replaced with fresh 
medium. The collected culture media were quantitatively analysed using assay kits 
for IL-6, IL-8 (BioLegend, San Diego, US) and LDH (Sigma Aldrich, Saint Louis, US) 
according to manufacturer`s protocol [110–112]. For the detection of IL-1α the 
supernatant of a skin tissue lysate was used. For this, each tissue was completely 
immersed in 0.5 mL cold lysis buffer-protease inhibitor mix (for detailed composition 
see appendix), homogenised with a pellet pestle for 40 s at 425 rcf and centrifuged 
(20817 rcf, 10 min, 4 °C) to pellet debris [113]. The supernatant as well as the culture 
media samples were aliquoted and frozen at -80 °C until use. The detection of IL-1α 
was performed after 24 h incubation time because of total tissue destruction following 
the instructions from manufacturer`s protocol [114]. All samples were analysed in 
duplicate. One EFT-400 tissue of each test formulation was collected after 8 h and 
prepared as paraffin embedded and H & E stained samples (chapter 3.2.6).  
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4 RESULTS 
4.1 Formulation Development and Characterisation 
The development of a dermal formulation containing protein drugs comprises some 
obstacles. On the one hand their high molecular weight and hydrophilic character 
complicate the penetration into skin; on the other hand the flexible and sensitive 
structure which is prone to external conditions is oftentimes responsible for a short 
shelf-life [4]. This study focused on the development of a topical formulation which 
facilitates the application of proteins with a high tendency for hydrolysis like the family 
of bacterial collagenases.  
Nevertheless, in case of containing an instable protein, a topic formulation must 
ensure high drug stability, solubility as well as good penetration and spreading 
properties on the patients` skin. Kogan et al. (2006) presented microemulsions as 
promising systems with the previously mentioned characteristics [65]. In comparison 
to emulsions and creams they have an advantageous thermodynamic stability 
beneath an easy preparation because of their spontaneous formation without any 
energy input [115]. Due to this spontaneous formation upon mixing the ingredients, it 
was envisaged to create an application system based on two separated phases 
within this project. A water-free pre-formulation (microemulsion concentrate) offers 
the opportunity to suspend the protein in the lipophilic phase separated from the 
aqueous phase. The mixing of those two phases should be performed directly before 
the application on skin, hence the contact time between protein and water, which is 
critical regarding the protein stability, is minimised. 
It is envisaged to combine the application of the formulation with a microneedling 
step (chapter 1.1). The resulting superficial damages increase the sensitivity of 
human skin. Therefore, it is crucial in the process of formulation development to 
select ingredients with a low potential of skin irritation.  
The process of formulation development including the formulation characterisation 
and in vitro tolerability studies will be described in following sections. A detailed 
discussion of obtained results will be held in the subsequent chapter 5. 
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4.1.1 Microemulsion Development 
The term "microemulsion" (ME) has been defined diversely by various authors [65]. 
This study follows the definition of Danielsson and Lindman in 1981 [116]: “(...) a 
microemulsion is a single, optically isotropic structured solution of surfactant, oil, and 
water.” 
Kogan et al. (2006) emphasised the versatile properties of ME such as 
thermodynamic stability, easy formation and a low viscosity with Newtonian 
behaviour [65]. The pronounced stability of these systems generally depends on the 
high content of surfactants. Quite a number of well-known non-ionic surfactants raise, 
however, skin irritations, especially in the chronical treatment, thus alternatives for 
the present investigations need to be found [117].  
Mild production processes and high environmental compatibility along with low 
irritation potential are frequently named reasons for the application of natural 
surfactants [65,115,117,118]. According to Paolino et al. (2002) natural surfactants of 
choice are phospholipids due to their good skin tolerability next to penetration 
enhancing effects [119]. The ability of phospholipid-based surfactants to stabilise 
microemulsions is already well reported in literature [62,115,118]. This study focused 
on the application of Lip80 (DAPL with 80 % of MAPL). The high amount of MAPL 
leads to a high polarity of the phospholipid and promises self-emulsifying properties 
with a great emulsification power (chapter 1.1.1.1). 
To exploit Lip80-based microemulsions for dermal protein delivery it was desired to 
produce systems that form stable microemulsions over a wide range of oil and water 
concentrations. Of particular importance was a high hydrophilic concentration range, 
to facilitate a complete solubility of water-soluble catalase. In addition, variations over 
a wide hydrophilic range mean superior microemulsion stability besides better 
application stability on skin, e.g. changes in water content as consequence of 
hydration and dehydration processes could be balanced easier.  
50 mM PBS pH 7.0 was set as hydrophilic phase instead of purified water because of 
its positive effect on model proteins solubility and stability [120]. Lip80 was 
determined as surfactant. Furthermore, a suitable additive to dissolve the 
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phospholipid as well as a lipophilic phase had to be selected to finally create a ME 
with the desired properties.  
4.1.1.1 Screening of Cosolvents 
Lip80 consists of yellow wax-like agglomerates. For processing this emulsifier in MEs 
a dissolving step is necessary. Short chain alcohols, e.g. 2-propanol, were already 
mentioned in literature to be suitable cosolvents [62,121].  
Due to their low irritation potential on skin and dissolving properties for Lip80, the 
following alkyl alcohols next to a polyethylene glycol were screened in ratios of 1:1, 
2:1 and 1:2 (surfactant:cosolvent):  
• Propylene glycol 
• Ethanol 99.9 % (V/V) 
• 2-Propanol 
• Macrogol 400 
Regarding the predefined ratios, Lip80 and a cosolvent were weighed in and stirred 
for 12 h at 22 °C. At the end, all agglomerates must be dissolved completely.  
Macrogol 400 was not able to dissolve the surfactant in either of the tested ratios. For 
the alkyl alcohols, the ratio of 2:1 (surfactant:cosurfactant) resulted in incompletely 
dissolved samples. The reverse ratio with higher cosolvent amount (1:2), resulted in 
a dissolved surfactant but no subsequent ME formation was observed. Surfactant 
and cosurfactants in a ratio of 1:1 lead to completely dissolved samples. Moreover, a 
formation of ME systems could be achieved for all alkyl alcohols. This ratio was most 
promising and used accordingly for further investigations. 
In order to find the concentration range of components (Lip80/alkyl alcohol:lipophilic 
phase:PBS) where they form ME, a pseudoternary phase diagram was constructed. 
As shown in Figure 17 he components are plotted on an x-, y- and z-axis, 
respectively. Together, they build a triangular shaped diagram, with 100 % of one 
component in each vertex. As predefined in the pseudoternary diagram the 
ingredients were calculated in fixed ratios (%, m/m) and combined in 10 % steps for a 
first cosolvent screening. 
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At ambient conditions, Lip80 was completely dissolved under stirring in a cosolvent. 
Afterwards, oil and PBS were added in parts as predefined in the pseudoternary 
diagram. These final mixtures were gently shaken as ME formation should occur 
spontaneously and inspected visually. A slightly to strongly turbid sample indicates 
the presence of a two-phase system whereas a ME is a clear to opalescent coloured, 
single-phase formulation such as defined by Danielsson and Lindman [116].  
Figure 17 presents the titration results of Lip80 dissolved in propylene glycol 
combined with two different lipophilic phases. The combination with Labrafac™ 
Lipophile WL 1349 (Figure 17, A) and LabrafacTM PG (Figure 17, B) showed small 
ME areas (labelled grey).  
 
Figure 17. Pseudoternary phase diagrams show ME areas with Lipoid S LPC 80 (Lip80), propylene 
glycol and as lipophilic phase (A) LabrafacTM Lipophile WL 1349 or (B) LabrafacTM PG. The grey areas 
label the formation of isotropic microemulsions. 
Formulations with Labrafac™ Lipophile WL 1349 (shown in Figure 17, A) required at 
least 60 % of surfactant/cosolvent whereas the mixtures with LabrafacTM PG (Figure 
17, B) need a minimum of 70 % to stabilise a ME. Formation of ME systems in this 
experimental setting was enabled at 10 % of PBS. 
Using ethanol 99.9 % (V/V) as cosolvent ME areas changed (Figure 18). The 
formation of isotropic areas was more pronounced with LabrafacTM PG (Figure 18, B) 
than Labrafac™ Lipophile WL 1349 (Figure 18, A).  
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Figure 18. Pseudoternary phase diagrams show ME areas with Lipoid S LPC 80 (Lip80), ethanol 
99.9 % (V/V) and as lipophilic phase (A) LabrafacTM Lipophile WL 1349 or (B) LabrafacTM PG. Isotropic 
areas (highlighted in grey) are most pronounced in diagram (B). 
The combination with LabrafacTM PG facilitated more variations of ingredient 
concentrations, especially of the hydrophilic phase with 10 % to 30 %. Using ethanol 
99.9 % (V/V) enabled the stabilisation of 30 % PBS with 60 % 
surfactant/cosurfactant. 
Less suitable was the utilisation of Labrafac™ Lipophile WL 1349 for the formation of 
isotropic areas (Figure 18, A). Variations of the three phases were more limited 
compared to Figure 17, A. 
The efficiency of forming ME increased by dissolving Lip80 in 2-propanol. As shown 
in Figure 19, A even the combination with Labrafac™ Lipophile WL 1349 led to the 
formation of larger isotropic areas compared to the other alkyl alcohols.  
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Figure 19. Pseudoternary phase diagrams show areas of ME formation with Lipoid S LPC 80 (Lip80), 
2-propanol and as lipophilic phase (A) LabrafacTM Lipophile WL 1349 or (B) LabrafacTM PG. Isotropic 
areas are highlighted in grey. The composition with the highest PBS content 50 %:10 %:40 % (m/m, 
Lip80/2-propanol:LabrafacTM PG:PBS) is encircled black. 
Regarding to the application of 2-propanol in Figure 19, A the PBS concentration was 
twice as high as in Figure 17, A and in Figure 18, A. More variations in the content of 
lipophilic and surfactant phase were possible. The exchange of the lipophilic phase 
increased the ME area even further (Figure 19, B). The application of 10 % 
LabrafacTM PG and 50 % surfactant/cosurfactant enables the stabilisation of 40 % 
hydrophilic phase. Therefore, this composition was used for dissolution experiments 
with 1 % catalase.  
Catalase was suspended in a mixture of 50 % Lip80/2-propanol and 10 % 
LabrafacTM PG, 40 % of PBS were added and the suspension was shaken carefully. 
Nonetheless, the content of hydrophilic phase was not big enough for a complete 
dissolution of 1 % of enzyme as envisaged in the aims.  
4.1.1.2 Optimisation of Microemulsion Area 
To increase the PBS content in ME formulations and correspondingly the solubility of 
model protein, the influence of further lipophilic ingredients was examined. Besides 
LabrafacTM PG, oily vehicles like PeceolTM, MaisineTM 35-1 as well as Plurol Oleique 
CC 497 (PO CC 497) were selected. Starting with the necessary PBS concentration 
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(for dissolving the enzyme) of 50 % and a reduced oil phase of 5 %, Lip80/2-propanol 
were added until 100 %. 
Figure 20 represents formed ME systems with maximal possible hydrophilic capacity. 
The oil content was fixed at 5 %, whereas the hydrophilic range was increased in 5 % 
steps and the content of surfactant/cosolvent decreased correspondingly.  
 
Figure 20. Property of different lipophilic ingredients to form microemulsion systems with an increasing 
hydrophilic content. The oil content was fixed to 5 %, whereas the PBS concentration was increased, 
the content of surfactant/cosolvent decreased correspondingly (not shown).  
PeceolTM- and MaisineTM 35-1-based MEs stabilised 60 % of incorporated PBS 
(Figure 20). In contrast, LabrafacTM PG contained a maximum of 65 % hydrophilic 
phase and PO CC 497 70 %.  
LabrafacTM PG and PO CC 497 formed MEs with the highest hydrophilic phase 
content. Figure 21 depicts more precisely titrated (5 % steps) ME areas of 
LabrafacTM PG in diagram A next to PO CC 497 in diagram B. 
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Figure 21. Pseudoternary phase diagram formed with oily vehicles (A) LabrafacTM PG and (B) 
PO CC 497. The formed isotropic areas are marked in grey. 
Figure 21, A presents a small hydrophilic isotropic area. A content of PBS larger than 
45 % formed ME systems only with 5 % of LabrafacTM PG. The hydrophilic ME area 
in Figure 21, B is more distinct. In a concentration range from 45 % to 60 % PBS, the 
content of PO CC 497 could be varied from 15 % to 30 %. 
Both systems stabilised more than 50 % PBS, thus they were suitable for the 
dissolution of 1 % catalase.  
4.1.1.3 PEGylated Microemulsion Systems 
It was envisaged to compare the phospholipid based ME to a formulation based on 
PEGylated surfactants in tolerability studies with reconstructed human skin 
(chapter 4.3). This system needs to include the same ingredients in a similar 
composition, only the natural surfactant Lip80 is exchanged.  
According to the experience of Kogan et al. (2006) forming ME with nonionic 
surfactants, in this study Polysorbate 80, Span® 20 and Kolliphor® EL were selected 
and tested in following combinations presented in Figure 22 [65]:  
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Figure 22. General chosen strategy for combinations of surfactant, 2-propanol and lipophilic phase.  
All surfactants or surfactant combinations were dissolved in 2-propanol (in equal 
proportions) and mixed with the two most promising lipophilic phases LabrafacTM PG 
and PO CC497, respectively (Figure 22).  
Figure 23 represents the titrated isotropic areas of the mixture Polysorbate 80 and 
Kolliphor® EL (ratio 1:1) combined with LabrafacTM PG (diagram A) as well as 
PO CC 497 (diagram B). Applying this surfactant combination, ME areas with the 
highest PBS capacity were formed. 
 
Figure 23. Comparison of two ME areas (marked grey) based on (A) LabrafacTM PG and (B) Plurol® 
Oleique CC 497 (PO CC 497).  
The comparison of both diagrams displays an extended isotropic area for the 
application of PO CC 497 (Figure 23, B). The superior properties of PO CC 497 
confirmed the observations made on the Lip80 system in Figure 21, B. Contrary to 
the more hydrophilic phospholipid ME (Figure 21, B), the PEG-based system showed 
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a more lipophilic ME (Figure 23, B). Although, a maximum concentration of 65 % 
PBS was stabilised by the PEG system, hydrophilic variations were more restricted 
compared to Lip80 system. 
Because of its more promising performance PO CC 497 was chosen as lipophilic 
phase for both surfactant systems. A composition of 35 %:5 %:60 % (m/m, 
surfactant/cosolvent:PO CC 497:PBS) was selected for comparison on both ME 
systems in later investigations. These developed formulations were promising for a 
good solubility of model enzyme. Figure 24 gives an overview of the PEG-based and 
Lip80-based ME areas with the selected concentrations (encircled black).  
 
Figure 24. Comparison of the final ME systems. Diagram (A) shows the PEG-based ME area next to 
diagram (B) with the Lip80 formed area. Compositions resulting in ME formation are marked grey and 
the final selected compositions are encircled black. 
4.1.2 Microemulsion Characterisation 
4.1.2.1 Multiple Light Scattering 
In order to confirm an optically clear, isotropic nature indicating ME formation 
(definition by Danielsson and Lindman [116]), transmission values of Lip80-ME and 
PEG-ME were measured with TurbiScanTM LAB. All investigations with TurbiScanTM 
LAB were performed with protein-free formulations.  
Images in Figure 25 illustrate the gradations between optically clear ME and turbid 
macroemulsions. Transparent systems like isotropic ME do not interfere with the 
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laser light, hence transmission values (T-value) are ≥ 80 % (red line Figure 26). 
Turbid macroemulsions show significant decreased transmission values smaller 
than 80 %.  
 
Figure 25. Lip80-ME and PEG-ME are depicted next to macroemulsion systems with slightly different 
compositions. Each image shows the ratio of ingredients in % (m/m), listed as surfactant/cosolvent:PO 
CC 497:PBS. (Scale bar = 20 mm) 
ME formulation results were compared to T-values of pure ingredients, PO CC 497, 
and PBS (Figure 26). PO CC 497 slightly deflects the laser light, resulting in the 
lowest transmission (85.6 %). A T-value of 91.3 % was measured for the more 
transparent aqueous PBS.  
 
Figure 26. Transmission values of multiple light scattering measurements with TurbiScanTM LAB. The 
test formulations Lip80-ME and PEG-ME are plotted against pure PO CC 497 and PBS. Each column 
presents the mean of three measurements and error bars present the standard deviation. All groups 
were calculated with ANOVA as not significantly different, p > 0.05. Red line refers to the determined 
minimum T-value indicating the presence of an isotropic system. 
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Measurements of both ME formulations obtained transmission levels higher than 
80 %. The optical transparency of Lip80-ME (91.3 %) as well as PEG-ME (91.0 %) 
was confirmed. Figure 26 demonstrates a similar transmission level of all samples, 
depicting no significant differences.  
The ME systems should be prepared directly before the preparation is administered 
on the skin. Hence, the product stability must be ensured for the application process 
and penetration period. In case of destabilisation phenomena e.g. phase separation, 
a shift in T-values would detect this. The formation of new interfaces is a global 
phenomenon taking place everywhere in the sample. Therefore, it is important to 
monitor the whole sample volume. Figure 27 represents the transmission profiles of 
tested formulations over 24 h.  
 
Figure 27. Transmission profiles of PEG-ME (A) and Lip80-ME (B). Data are reported as a function of 
time (0-24 h) as well as sample height (2-16 mm). 
RESULTS 
52 
 
Bottoms of glass vials besides the meniscus of formulations were excluded from the 
evaluations. Black lines in Figure 27 frame the screened sample area from 2 to 
16 mm. It is clearly visible that no increase or decrease in T-values occurred. In 
Figure 27 diagrams A and B show stable formulations over the complete 
measurement time. 
4.1.2.2 Dynamic Light Scattering 
Table 2 lists characteristic physical properties of ME systems like viscosity (Vibro 
Viscometer SV-10, A&D Company Limited, JPN), refraction index (manual Abbe 
Refractometer) and density (m/V) which were performed and used for the 
examination of dynamic light scattering. They are also important for the prediction of 
application behaviour, e.g. pipetting or spreading on human skin.  
Table 2. Selected physical properties of Lip80-ME and PEG-ME. All measurements were performed 
at 22 °C. 
Test system Viscosity 
η (mPa*s) 
Refractive Index 
nT
D (°) 
Density 
ρ (g/mL) 
Lip80-ME 11.33 1.37 0.97 
PEG-ME 23.53 1.37 0.97 
 
The determined dynamic viscosity of PEG-ME was twice as high as Lip80-ME (Table 
2). These deviations are probably based on different surfactant structures and their 
varying viscosities. Compared to purified water (0.98 mPa*s, 22 °C) and PO CC 497 
(2063 mPa*s, 22 °C) the formulations were of rather low viscosity. However, the 
results of refractive index and density were identical.  
The physical parameters in Table 2 are crucial for droplet size calculations via 
dynamic light scattering technique and subsequent evaluations of ME systems 
microstructure. Figure 28 shows the intensity distribution of PEG-ME (A) and  
Lip80-ME (B) obtained in triplicate. 
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Figure 28. Intensity size distribution of tested ME. (A) shows peaks of droplet size measurements of 
PEG-ME and diagram (B) of Lip80-ME. (n = 3) 
The results presented reproducible intensity patterns with calculated z-average 
diameters of 1.4 nm (A) and 1.2 nm (B), respectively. PDIs above 0.1 (PEG-ME 
0.1 < 0.5 and Lip80 0.1 < 0.3) demonstrated a broad scattering of particle sizes and 
confirmed the bimodal distribution of both formulations, shown in Figure 28. 
Distribution curves of diagram A and B are characterised by a decreased intensity 
pattern to higher droplet sizes (second peak). Despite the property of large particles 
to scatter the light much more than small particles, the signal intensity is considerably 
low compared to smaller particles Hence, first peaks around 1 nm represented the 
dominant droplet sizes of ME formulations. 
Stability measurements over 24 h resulted in no changes of droplet sizes as well as 
intensity distributions (for comparison of z-average 0 h/24 h and PDI 0 h/24 h data 
see Appendix (chapter 8.3).  
Figure 29 shows the intensity size distribution of ME systems obtained by dilution of 
pre-concentrated lipophilic suspensions with PBS. 1 mg/mL of catalase was 
suspended in the lipophilic-surfactant/cosolvent pre-formulation. Protein-loaded ME 
diagrams are overlaid with distributions curves of pure formulations (red dotted lines 
in Figure 29, A and B). 
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Figure 29. Overlaid plot of the pure ME (red dotted lines) and ME containing dissolved catalase 
(black/grey). Diagram (A) represents measured particle size distribution of PEG-ME next to diagram 
(B) with the results of Lip80-ME. (n = 3) 
In Figure 29 diagram A and B an additional peak arises at approximately 0.3 microns, 
caused by the dissolved protein. Compared to the unloaded formulation curves (red 
dotted lines), protein-loaded ME curves showed a shift to smaller particle sizes as 
well as a redistribution of peak intensities. Particularly, the intensity profile of  
PEG-ME (Figure 29, A) presented three peaks with almost the same intensity 
distribution. The incorporation of catalase in PEG-ME led to an increase of large 
particles which concurrently weakened the signal intensity of smaller droplets.  
In Figure 29, B the shift of second peak is most pronounced. Following the 
dissolution of protein in Lip80-ME, particle sizes altered from a z-average of 57 nm to 
8 nm. Contrary to the evenly distributed intensities of PEG-ME, the signal intensities 
of Lip80-ME, especially the peaks at highest sizes, displayed strong fluctuations 
between measurement repetitions. 
In consideration of present intensity detections (Figure 29, A and B) protein-loaded 
MEs showed a bimodal particle size distribution, whereas the dissolution of the 
model enzyme in MEs led to a multimodal distribution. Both ME systems, protein-
loaded and -unloaded, presented very small droplets in a range of 1 nm. 
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4.1.3 Analysis of Protein Stability in Microemulsion Systems 
In this study stability analysis includes not only the assurance of formulation stability 
during the application period but the control of API stability as well. Characterisations 
of ME formulations stability were already described (chapter 4.1.2). Following 
chapters will present various methods to analyse the behaviour of model protein in 
the ME systems. 
4.1.3.1 Catalase Activity Assay 
The suitability of photometric determinations to detect changes in catalase activity 
was examined utilising targeted destabilisation processes.  
As positive control 1 % of enzyme was diluted in 50 mM PBS pH 7.0. Figure 30 
depicts three single sequent measurements at pH 7.0, 25 °C, while one experiment 
took approximately 5 min. In the preferable environment, the maximum measurable 
activity was 3584 U/mg (equation (2), chapter 3.2.5). As shown in Figure 30 even the 
optimal value was subject to variations (n = 3, 3584 U/mg ± 186 U/mg).  
 
Figure 30. Catalase activity analysis under various conditions; pH 7.0/25 °C, pH 3.5/25 °C and 
pH 7.0/50 °C Single data of sequent performed measurements are displayed. 
An acid-treatment of the 1 % catalase solution induced a first destabilisation. The 
enzyme was diluted in 50 mM PBS pH 7.0 and afterwards acidified with phosphoric 
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acid to pH 3.5. In an acidic environment catalase showed an immediately started 
inactivation of 50 % after 5 min (1812 U/mg, Figure 30). After 10 min and 15 min 
contact time the activity decreased from 1127 U/mg to 563 U/mg, continuously. In 
comparison to a stable solution at pH 7.0, the total loss of enzyme activity after 
15 min acid-treatment was 84 %. Between 10 min to 15 min catalase started to 
precipitate from the acidic solution. This visible enzyme degradation process 
confirmed the loss of activity. 
A slower reduction of catalase activity was examined for heating of the stable 1 % 
catalase solution pH 7.0 up to 50 °C (Figure 30). Monitored in 5 min steps also, the 
substrate turnover started at 3423 U/mg and was calculated to 2529 U/mg, finally 
after 15 min. Under these conditions a total loss of activity of about 29 % and no 
enzyme precipitation were observed. 
ME formulations stabilised with Lip80 or PEGylated surfactants were prepared, 
including 1 % of model enzyme. Activity values were calculated in % with respect to 
100 % activity of an unchanged 1 % phosphate-buffered catalase solution pH 7.0 
(positive control, Figure 31 and Figure 32). Figure 31 demonstrates the decrease of 
enzyme activity in Lip80-ME over 24 h at ambient conditions. Changes were detected 
directly after mixing the final protein-loaded ME (0 h) and frequently every hour for 
the first 3 hours storage time and then again after 18 h and after 24 h, respectively.  
 
Figure 31. Time-dependent changes of catalase activity in Lip80-ME. The activity is calculated in 
comparison to a positive control, set as 100 % activity. n = 3, error bars indicate the standard 
deviation. 
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The most pronounced decrease of 24 % was observed during the first hour after 
preparation. In the subsequent monitored storage time, catalase activity varied 
around an activity of 60 %. 
In following experiments the influence of the PEGylated ME on model enzymes 
activity was examined at ambient conditions (Figure 32). Compared to the 
phospholipid-based system this formulation showed a strong inactivation of 62 %, 
directly after the preparation (0 h). 
 
Figure 32. Time-dependent changes of catalase activity in PEG-ME. The activity is calculated in 
comparison to a positive control, set as 100 % activity. n = 3, error bars indicate the standard 
deviation. 
During the following 24 h catalase continuously lost its activity from 1497 U/mg (0 h) 
to 812 U/mg (24 h). The overall loss of enzyme activity in PEG-ME after 24 h was 
79 % compared to the positive control.  
Enzyme precipitations from both ME formulations were not observed. It was 
assumed that the detected decrease of the substrate turnover of catalase was due to 
structural alterations of the enzyme.  
4.1.3.2 Size Exclusion Chromatography 
Catalase is a tetrameric structured enzyme with a total molecular weight of 
approximately 240 kDa [23]. In Figure 33 the size exclusion chromatography (SEC) 
profile of a stable phosphate-buffered catalase solution pH 7.0 is shown.  
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The chromatogram of catalase is characterised by a major peak with a corresponding 
peak shoulder at a retention time (Rt) of 16 min. Using calibration standards between 
2000 kDa (blue dextran) and 13.7 kDa (ribonuclease A) it was possible to classify the 
molecular size of the catalase peak.  
 
Figure 33. SEC profiles of bovine liver catalase and molecular weight standards (1-4). Arrows in the 
catalase chromatogram mark the retention time of molecular weight markers: (1) blue dextran 
2000 kDa; (2) bovine serum albumin 67 kD; (3) ovalbumin 42 kDa; and (4) ribonuclease A 13.7 kDa. 
Catalase elutes as monomer with a molecular weight of 60 kDa between (2) and (3). 
As shown in Figure 33 the catalase peak eluted between bovine serum albumin and 
ovalbumin. Thus, catalase was detected as monomer with a molecular weight of 
60 kDa (chapter 3.1.3). 
Besides the calibration of the measuring range it was required to determine the 
sensitivity of the chosen setup in detecting 3D-structural changes within the enzyme. 
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As already conducted in chapter 4.1.3.1, acid and heat stress tests were applied to 
induce a denaturation and to determine changes in detection signals (Figure 34).  
 
Figure 34. SEC profiles of bovine catalase under various conditions. Arrows mark regions of interest 
with loss of signal intensity (arrow at Rt 16 min) or the elution of new peaks (arrow at Rt 20 min).  
The reduction from pH 7.0 to 3.5 led to protein destabilisation. The major peak is 
assigned to the catalase monomer and minor peaks correspond to destabilised parts 
of the protein structure. With longer storage time at pH 3.5 the protein lost its native 
structure and the solubility in an aqueous environment decreased, thus it started to 
precipitate. Insoluble, precipitated parts of the protein stayed in the SEC column and 
caused a decreased signal intensity (chapter 4.1.3.1).  
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The SEC profile of catalase at 50 °C showed less structural changes of the protein 
compared to the signal detected at 60 °C. When the temperature was increased the 
amount of destabilised protein parts increased, too. Concurrently, the intensity of 
peaks decreased, due to the starting precipitation.  
SEC analyses of catalase under various conditions resulted in peaks of degraded 
protein structures at a similar Rt of 20.3 min. The molecular weight of detected 
structures must be lower than the molecular weight of ribonuclease A (13.7 kDa), 
because it eluted approximately 2 min earlier (Figure 33).  
These investigations proved the ability of SEC to detect changes in protein structure. 
Further analyses dealt with the challenges to determine the behaviour of protein in 
ME formulations. It is essential to differentiate between signals from catalase 
monomer or its degradation products and those originating from formulation 
excipients. Figure 35 depicts the chromatograms of Lip80-ME (Figure 35, A) and 
PEG-ME (Figure 35, B) excipients. 
 
Figure 35. Chromatograms of pure (A) Lip80-ME and (B) PEG-ME excipients. The catalase solution 
pH 7.0 is plotted in each diagram as comparison. 
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Both diagrams in Figure 35 (A and B) show that the lipophilic phase PO CC 497 
generated a small signal at a Rt of 21 min. The surfactant/cosolvent mixture of each 
ME formulation induced a high signal with a large peak area. Compared to catalase 
pH 7.0, Lip80/2-propanol appeared earlier at 10 min with a strong tailing besides a 
splitted top (Figure 35, A). The signal intensity of the PEG/2-propanol peak was 
much higher than the Lip80/2-propanol peak (Figure 35, B). The signal of  
PEG/2-propanol was splitted into two incompletely seperated peaks, whereas the 
main peak appeared simultaneously with the signal of catalase monomer. 
The complete formulation Lip80-ME placebo eluted as a smaller and uniformly 
shaped peak compared to the single surfactant/cosolvent phase. Despite different 
peak shapes both signals were detected at the same Rt (10 min). Afterwards, the 
PO CC 497 signal appeared unchanged at 21 min. The catalase monomer eluted 
between the surfactant- and lipohilic phase signal, hence there is no risk of an 
overlapping of signals.  
It was shown, that the signals of excipients injected solely differed from the 
chromatogram of formulated ME. This also holds true for the measurements of  
PEG-ME in Figure 35, B. While PO CC 497 eluted unchanged at 21 min, the signals 
of surfactant/cosolvent phase and the final ME were different compared to those 
detected in diagram A. PEG-ME placebo eluted in two overlayed peaks and a slightly 
shifted Rt compared to the signal of PEG/2-propanol phase. However, the  
SEC-chromatogram of PEG-ME placebo overlapped the signal of catalase. This 
simultaneous elution complicated the identification of changes in the structure of 
enzyme. 
In following experiments, ME formulations were loaded with 1 % catalase and 
examined regarding their influence on the enzyme structure. Time-dependent 
analyses of catalase stability in Lip80-ME (diagram A) as well as in PEG-ME 
(diagram B) are depicted in side-by-side chromatograms in Figure 36.  
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Figure 36. SEC graphs of time-dependent analyses of catalase changes in (A) Lip80-ME and (B) 
PEG-ME. 
Protein-loaded ME formulations were prepared and injected directly (0 h), 3 h later 
and after 24 h, respectively.  
Directly after preparation of the phospholipid-based ME (0 h) the detected 
chromatogram can be characterised by three incompletely separated peaks (Figure 
36, A). Initially, at approximately 10 min, Lip80/cosolvent phase eluted as a small 
peak before the catalase monomer signal at 16 min. Afterwards, the lipophilic phase 
appeared with its typical low signal intensity. The sample representing the ME 
3 hours after preparation showed an increased surfactant peak, shaped like the 
signal of pure components (Figure 35, A). The other two signals (catalase monomer, 
lipophilic phase) appeared in a similar size and Rt compared to Lip80-ME directly 
after preparation. 
Lip80-ME 24 h presented a more pronounced tailing of the first peak and a lower 
recovery of the catalase peak. Contrary to measuring times at 0 h and 3 h,  
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the lipophilic phase appeared in an increased peak signal. Changes of enzyme 
structure with a redistribution of molecular sizes were assumed. One part of 
destabilised protein formed smaller degradation products next to catalase monomer 
and eluted later. This shift in Rt led to an overlapping with the PO CC 497 signal and 
hence an increase in intensity. Instabilities of protein structure caused also the 
formation of larger protein aggregates, they eluted earlier compared to catalase 
monomer and overlapped with the signal of surfactant/cosolvent phase increasing 
the intensity of peak, too.  
In comparison to previous analysed Lip80-ME the interpretation of SEC results of 
protein stability in PEG-ME (Figure 36, B) was more challenging. The examination of 
SEC signals induced by catalase or its degradation products was complicated by the 
peaks of PEG-ME which eluted at same retention times. 
The chromatogram of protein-loaded PEG-ME 0 h was characterised by two 
incompletely separated major peaks and a minor peak. The major peak 
corresponded to two retention times: a signal at 13 min and another one, 
corresponding to the catalase monomer at a retention time of 16 min. This peak was 
linked to a minor peak (Rt = 21 min) corresponding to PO CC 497. In Figure 35, B no 
signal was observed matching the first peak at 13 min. It was assumed that this peak 
is a combination of the PEG-ME signal and large protein aggregates. The ongoing 
shift of SEC signals to earlier retention times at 3 h and 24 h after preparation 
confirmed this hypothesis. However, the catalase peak at 0 h looked like the pure 
catalase signal at pH 7.0. 3 h later the peak eluted with a larger area and was more 
irregular shaped. A completely altered separation profile of PEG-ME was detected 
after 24 h. One major peak at 14 min indicated severe changes of ME formation and 
enzyme structure.  
SEC measurements of protein-loaded Lip80-ME and PEG-ME demonstrated the 
challenges of protein stability analysis out of "multicomponent" mixtures like MEs with 
an interfering potential. Overlapping signals were especially observed in the SEC 
profiles of PEG-ME including 1 % catalase. 
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4.1.3.3 nanoDSF 
To verify changes in protein stability within ME formulations the ratio of fluorescence 
intensities at 350 nm and 330 nm (conformational stability) as well as the 
backscattering intensities (colloidal stability) were examined. As performed in 
previous investigations (chapter 4.1.3.1 and 4.1.3.2), nanoDSF measurements 
utilised acid and heat stress to induce protein degradation. The F350/F330 ratio of 
stable (pH 7.0) as well as destabilised (pH 3.5) catalase are plotted in Figure 37, A 
and B.  
In contrast to destabilised catalase at pH 3.5, the sample at pH 7.0 presented a 
measurable thermal unfolding transition. The inflexion point in the curve of 
fluorescence ratio (Figure 37, A) and correspondingly the peak of the first derivative 
(Figure 37, B) are defined as the unfolding transition temperature Tm which was 
found to be at 56 °C for the stable catalase solution. However, no peak in the first 
derivative and hence no defined melting temperature could be found for the 
destabilised protein sample. Figure 37, C shows the tendency of protein aggregation 
in test solutions. Whereas the sample at pH 7.0 presented a low signal of scattered 
light (0.108 A.U. at 20 °C), the intensity increased with increasing destabilisation. 
Already the initial value of 0.158 A.U. (at 20 °C) of protein solution at pH 3.5 was 
higher demonstrating a loss of colloidal stability. 
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Figure 37. Conformational stability and aggregation of bovine liver catalase at optimal pH 7.0 and 
destabilising pH 3.5. Diagram (A) shows the ratios of fluorescence intensities at 350 nm and 330 nm 
of both catalase formulations. (B) presents the first derivative of (A), the arrow indicates Tm at 56 °C of 
buffered catalase solution. (C) depicts the aggregation detected by changes in backreflection.  
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Thermal unfolding curves of protein-loaded ME formulations are presented in Figure 
38. The resulting unfolding signals in F350/F330 ratio showed two different profiles 
generated by the ME-systems (Figure 38, A and B). 
 
Figure 38. Ratios of fluorescence intensity at 350/330 nm present thermal unfolding curves of catalase 
in (A) Lip80-ME and (B) PEG-ME. Changes in conformational stability are examined at 0 h, 3 h and 
24 h.  
A clearly defined transition of Lip80-ME curves was detectable up to 24 h after 
preparation (Figure 38, A). PEG-ME curves were characterised by transitions with a 
smooth progression comparable to the destabilised catalase solution at pH 3.5 
(Figure 37, A and Figure 38, B). 
Calculated Tm values at 0 h, 3 h and 24 h for Lip80-ME are listed in Table 3. The 
temperature at which half of the protein is unfolded was changed in Lip80-ME 
compared to the stabile protein structure at pH 7.0. 3 h after Lip80-ME preparation 
the structure of protein changed to an unfolding at higher temperature, whereas at 
24 h a declined Tm was detected. After 24 h the F350/F330 curves as well as the 
calculated Tm were like 0 h samples. No Tm was calculable for PEG-ME samples 
because of the smooth progression of fluorescence curves.  
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Table 3. Unfolding transition temperatures (Tm) and aggregation values (agg.) at 20 °C of catalase. 
Results are calculated after 0 h, 3 h and 24 h of ME preparation. 
 Lip80-ME PEG-ME 
 Tm (°C) Agg. (A.U.) Tm (°C) Agg. (A.U.) 
0 h 44.0 0.321 Unfolded 0.318 
3 h 52.0 0.214 Unfolded 0.422 
24 h 45.5 0.398 Unfolded 0.445 
 
Results of Lip80-ME and PEG-ME F350/F330 ratios demonstrated differences in 
conformational stability between the two systems. The loss of conformational stability 
and likewise the unfolding of enzyme were more pronounced in PEG-ME, presented 
by the missing transition points of fluorescence curves. Directly after PEG-ME 
preparation a main part of the enzyme was already unfolded. As shown in Figure 
38, B an increase of temperature did not led to further denaturation processes in 
PEG-ME 0 h.  
Changes in colloidal stability of enzyme in both MEs were also examined and are 
shown in the following section. Single backscattering values in A.U. at 20 °C enable 
an overview of the initial state of model enzyme in MEs (Table 3). Lip80-ME at 3 h 
showed a decreased backscattering value compared to the initial status at 0 h. Most 
pronounced was the colloidal instability after 24 h storage time resulting in the 
highest backscattering.  
PEG-ME showed increased aggregation behaviour with increasing measurement 
time (Table 3). Higher backscattering values of catalase in PEG-ME indicated a more 
pronounced colloidal instability compared to Lip80-ME. Figure 39 shows the 
progression of backscattering intensities with increasing temperature.  
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Figure 39. Aggregation behaviour of catalase in (A) Lip80-ME and (B) PEG-ME after 0 h, 3 h and 24 h. 
Backscattering curves of Lip80-ME at 0 h, 3 h and 24 h suggest an increase in 
aggregation with rising temperature (Figure 39, A). Above 50 °C formed enzyme 
aggregates seemed to dissolve, resulting in declining curves. The aggregation curve 
of catalase in PEG-ME at 0 h ran irregular, whereas after 3 h and 24 h curves 
showed a decrease (Figure 39, B) comparable to Lip80-ME curves. However, the 
highest backscattering values were measured in the initial state at 20 °C and started 
with rising temperature to decline as Lip80-ME in Figure 39, A. The observed peaks 
above 80 °C in Figure 39, B can be attributed to measurement artefacts caused for 
example by air bubbles in sample capillaries.  
Lip80-ME and PEG-ME presented changes in colloidal stability. But as already 
observed for conformational enzyme instabilities, colloidal instabilities in PEG-ME 
were more pronounced as in Lip80-ME.  
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4.2 Evaluation of a Needle Device 
In this thesis, it is envisaged to combine the application of a protein-loaded ME 
formulation with a prior microneedling step. Three needle devices (chapter 3.1.4) 
were examined regarding their reproducibility and efficiency in forming microchannels 
into human cadaver skin. Furthermore, the needle device should be suitable for the 
application in tolerability studies with 3D-human skin models. Special requirements 
here are the small skin surface (1 cm²) and the lateral boundary of the transwell 
system.  
The measurements were performed in comparison to a reference needle device. As 
reference a single-use, disposable needle for intramuscular injections (specification 
0.90 x 50 mm) was selected due to its strong potential to induce deep channels into 
the uppermost skin layers.  
4.2.1 Microchannel Morphology 
Heat-separated epidermis sheets (6.0 mm in diameter, ᴓ) were perforated with the 
different microneedle devices and the morphology of created pores was examined 
via scanning electron microscopy (SEM). SEM technique enabled the recording of 
top view images with a detailed view on pore shapes. 
SEM images of the reference sample are shown in Figure 40, A. The created pores 
are characterised by a V-shaped incision, comparable to a lancet cut. Mainly 
responsible for this was the bevelled needle tip of the used cannula.  
In comparison to the almost 100 µm long incision of the reference needle, the 
Dermaroller® created smaller pores of about 40 µm in diameter (Figure 40, B). A 
detailed view on the formed channel revealed an almost triangular shape (Figure 40, 
B detailed view). eDermastamp® and Dermastamp® (Figure 40, C and D) showed this 
shape as well, which was attributed to the same conical needle shape.  
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Figure 40. Scanning electron microscope images as top view on skin surface treated with (A) 
reference device (cannula, dimension 0.90 x 50 mm), (B) Dermaroller®, (C) eDermstamp® and (D) 
Dermastamp®. Images (scale bar = 100 µm) are depicted with a detailed view on the micropore (scale 
bar = 50 µm).  
Size and shape of microchannels formed by a rolling or stamping process were 
comparable (Figure 40, B and D). Largest pores were achieved by using the 
eDermastamp® (Figure 40, C). Responsible for this was the automatic prick-
frequency (100 pricks/min) during the piercing process. Besides bigger puncture 
sites, pores were characterised by frayed edges (Figure 40, C detailed view).  
The efficiency in microchannel creation was also examined by analysing channel 
depth via cross-sectional images (Figure 41). A defined area (5 x 5 cm) of full 
thickness human skin was treated with the needle devices. Afterwards, histological 
sections were prepared with a cryo-microtome and analysed by light microscopy 
without any further staining.  
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Figure 41. Bright field images of histological cross-sections of human skin treated with (A) reference 
device (cannula, dimension 0.90 x 50 mm) treated skin, (B) Dermaroller®, (C) eDermstamp® and (D) 
with Dermastamp®. The microneedles penetrated the skin (EP = epidermis, D = dermis) through the 
stratum corneum (SC) barrier as indicated by the arrows. (Scale bar = 50 µm) 
An image of a pore formed by the reference needle device is shown in Figure 41, A. 
The channel ranged from the SC to uppermost layers of dermis and was 
approximately 200 µm deep. The channel is characterised by a rough and frayed 
shape.  
Microchannels created by Dermaroller® were superficial and ranged with about 
50 µm only into epidermal layers (Figure 41, B). Compared to the channel formed by 
cannula, the Dermaroller® created regular shaped pores. Shaped similar, but with a 
wider puncture site was the microchannel created by Dermastamp® (Figure 41, D). 
With a pore depth of approximately 60 µm it pierced into the epidermis, too.  
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The channel formed by the automatically driven eDermastamp® (Figure 41, C) was 
around 120 µm deep. Compared to images B and D, the uniform shaped channel in 
C tapered towards the tip and achieved uppermost dermal layers.  
All types of microchannel devices had sharp tips and were strong enough to pierce 
the SC barrier of skin.  
4.2.2 Assessment of Skin Integrity 
TEWL is a parameter of skin barrier function and was employed to test the efficiency 
and reproducibility of microneedle devices to disrupt the integrity of SC. As baseline 
control and for calculation of skin disruption strength, the TEWL of intact skin was 
tested before device application. All measurements were subjected to statistical 
analysis to calculate differences between untreated and treated groups. Changed 
TEWL values were used to classify the strength of skin disruption.  
The continuous water loss of intact skin was found to be 19.13 ± 1.02 g/h/m², 
calculated as mean of all presented measurements (Figure 42).  
 
Figure 42. TEWL values of skin before and after treatment. The cannula (reference), eDermastamp® 
as well as Dermastamp® showed a significant increase in TEWL values compared to untreated skin 
samples (one-way ANOVA, not significant (ns) p > 0.05, *p ≤ 0.05, **p ≤ 0.01; n = 5). 
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The TEWL values of reference, Dermaroller®, eDermastamp® as well as 
Dermastamp® were measured immediately after treatment and found  
to be 26.03 ± 2.20 g/m²/h, 25.50 ± 2.34 g/h/m², 24.10 ± 2.14 g/h/m² and 
19.53 ± 1.24 g/h/m², respectively. A significant increase (ANOVA, *p ≤ 0.05, 
**p ≤ 0.01) in water loss was observed as result of microchannel formation in the skin 
by reference device, eDermastamp® and Dermastamp®, compared to untreated skin 
samples. Whereas the automatically and manually driven Dermastamps reached 
similar TEWL values to the cannula, the Dermaroller® was significant different 
resulting in the lowest SC disruption.  
Small standard deviations indicated a good reproducibility of the piercing by the 
devices. The best efficiency in forming microchannels (showing highest TEWL 
values) was achieved by eDermastamp®. 
Requirements for the needle device which had to be considered were a high 
reproducibility and efficiency in forming microchannels next to the use in tolerability 
studies with a small application area. The Dermaroller® presented an inefficient 
disruption of SC and needed a large skin area for its rolling application. Hence, this 
device was unsuitable for the use in tolerability studies.  
Best results were achieved by using the eDermastamp®, but its head was slightly 
bigger (ᴓ 1.1 cm) than the transwell system (ᴓ 1.0 cm). The Dermastamp® was finally 
chosen because of the smaller device head (ᴓ 0.90 cm), besides a comparable 
reproducibility and efficiency in forming microchannels to eDermastamp®.  
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4.3 Skin Tolerability Studies 
To examine the tolerability of developed Lip80-ME on human skin, the formulation 
was tested in combination with the selected needle device Dermastamp®. For 
comparison, a system based on PEGylated surfactants was applied and treated 
under equal conditions. The samples were tested on an EpidermTM FT skin model as 
described in chapter 3.2.8. The effects of the formulations on skin were characterised 
by investigating the immunologic response next to histopathological changes. Aim of 
the investigation was the prediction of in vivo skin irritation of the developed ME 
system combined with a microneedling process. Therefore, Lip80-ME and PEG-ME 
were prepared and analysed as protein-free systems. 
4.3.1 Cytokine and Cell Viability Analyses 
For the immunological assessment of Lip80-ME and PEG-ME different ways of 
application were tested. Table 4 presents an overview of applied test systems and 
their individual compositions.  
Table 4. Overview and compositions of applied samples in the tolerability studies.  
Sample Identification Ingredients/Application 
PBS Phosphate buffered saline pH 7.0  
(TC-PBS-100 by MatTek Corp.) 
SDS  0.8 % aqueous sodium lauryl sulfate solution 
Lip80-ME Placebo; 35 % Lipoid S LPC 80/2-propanol,  
5 % PO CC 497, 60 % PBS 
PEG-ME Placebo; 35 % Kolliphor® EL, Polysorbate 80/2-propanol, 
5 % PO CC 497, 60 % PBS 
Dermastamp® Piercing step 10 x 
Dermastamp® + Lip80-ME 1. Piercing step 10 x   
2. Application of test formulation 
Dermastamp® + PEG-ME 1. Piercing step 10 x  
2. Application of test formulation 
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PBS was chosen as a control group to demonstrate the influence of a well-tolerated 
and mild substance on 3D-human skin model. The opposite was represented by the 
application of a 0.8 % SDS solution. This control group was selected to induce a 
remarkably irritating effect on the skin model [122]. Listed samples in Table 4 were 
applied in triplicate on 3D-human skin and analysed after 3 h, 8 h and 24 h. To 
simulate extreme conditions, ME formulations were removed after the maximum 
period (24 h). 
In this thesis, IL-1α, IL-6 and IL-8 were selected as immunological markers to 
characterise the influence of developed application system (microneedle 
device + ME) on human skin. In response to physical or chemical stresses, 
keratinocytes and fibroblasts produce and release, inter alia, inflammatory cytokines 
(IL-1α), secondary cytokines (IL-6) as well as chemotactic cytokines (IL-8) [123]. For 
further information about immune functions of the skin, see chapter 2.1.1. 
IL-1α is a primary cytokine, contributively to the onset and maintenance of an 
inflammatory response. It stimulates the release of secondary mediators including  
IL-6 as well as IL-8 [124]. Figure 43 shows the IL-1α release after 24 h for all applied 
formulations.  
A comparison between PBS and SDS demonstrated a significant difference between 
these two control groups. Additionally, Lip80-ME and PEG-ME were significantly 
different to PBS. They showed an IL-1α concentration like SDS, hence they had a 
comparable irritating potential after 24 h contact time. 
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Figure 43. IL-1α response in ng/mL after 24 h. Each column presents the mean of three obtained 
single concentrations and bars indicate the standard deviation. Significance levels are shown for 
selected groups and calculated with a one-way ANOVA *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001. 
Treatment with the Dermastamp® did not show an increased level of IL-1α release 
compared to PBS. The same holds true for the combination Dermastamp® + PEG-
ME (Figure 43). However, the application of Dermastamp® + Lip80-ME presented an 
elevated concentration, which was even significantly higher than the SDS solution. 
IL-6 was chosen because of its crucial and versatile role in inflammatory processes 
caused by the pleiotropic property. Therefore, IL-6 is often used as a marker for local 
as well as systemic activation of proinflammatory cytokines [26,125].  
For the secretion of IL-8 the presence of full-thickness skin is necessary, enabling the 
communication between keratinocytes and fibroblasts. IL-8 plays an important role in 
endothelial cell proliferation processes and shows increased intracellular 
concentrations after cell damages [126]. Dermastamp® induced superficial damages; 
hence it was envisaged to use an increased IL-8 level as control parameter for the 
skin microporation. Figure 44 displays the results of IL-6 release (diagram A) next to 
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the concentrations of IL-8 response (diagram B). Generally, the profiles as well as 
the changes of interleukins response look similar in both diagrams. 
 
Figure 44. Release of inflammatory biomarkers (A) IL-6 and (B) IL-8 from EFT-400 tissue into culture 
medium 3 h and 8 h after application. Each column presents the mean of three obtained single 
concentrations and error bars indicate the standard deviation. Significance levels are shown for 
selected groups and calculated with a two-way ANOVA as not significant (ns) p > 0.05, *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.  
The release of IL-6 and IL-8 upon treatment with PBS did not show a statistically 
significant change between 3 h and 8 h confirming stable test conditions. The 
application of 0.8 % SDS led to a stimulation of inflammatory processes being 
detected as release of IL-6 and IL-8. PBS and SDS profiles started at a similar level 
of IL responses (3 h), however, after 8 h exposure time IL concentrations of SDS-
treated specimen increased and were statistically significant different compared to 
PBS. Thus, a clear induction of an inflammatory process of tested substances could 
be detected.  
Time-dependent changes between Lip80-ME and PEG-ME regarding their tolerability 
on human skin were not observed (Figure 44, A and B). After 8 h both formulations 
resulted in increased cytokine levels compared to PBS but were significantly different 
to SDS.  
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Interestingly, both diagrams in Figure 44 show an increased cytokine response after 
microneedle treatment compared to the combination of needling and the application 
of Lip80-ME. This change was significant for the detection of IL-6, whereas IL-8 
showed this effect less pronounced. PEG-based formulations did not exhibit these 
differences, neither after 3 h nor after 8 h exposure time.  
Microneedling is harmful, but the application of ME was able to reduce the local 
irritating effect [39]. Presented results showed that Lip80-ME was able to reduce this 
effect better than PEG-ME. The weakening influence of phospholipid-based ME on 
the needling process which was observed for IL-6 and IL-8 (Figure 44) was not 
detected for IL-1α. Different sample periods and varying roles of cytokines in the 
inflammatory cascade might be responsible for that.  
In addition to the measurement of IL-8 release the anticipated destructing effect of 
needle device on skin inserts was detected by analysing changes of lactate 
dehydrogenase (LDH) concentration in basolateral media. LDH was also quantified 
after 3 h and 8 h exposure time. LDH is an enzyme of cell cytosol. It catalyses the 
conversion of lactate to pyruvate, and vice versa [112]. LDH is an important 
parameter to control the integrity of cells: the higher the LDH concentration in 
medium, the more damaged is the cell [127].  
The assumed initial cell damage of microneedling is presented in Figure 45. Already 
after 3 h the LDH level induced by Dermastamp® treatment was significantly higher 
than those of all other treatments. Likewise, a statistically significant increase of LDH 
release upon needling was observed after 8 h being even higher than the SDS level.  
ME formulations did not increase LDH release compared to PBS, whereas the 
combination with Dermastamp® significantly increased LDH release after 8 h. 
However, these concentrations were not as high as in the sole use of Dermastamp®. 
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Figure 45. Changes in LDH release after 3 h and 8 h detected as mean of LDH activity in mU/mL. 
Error bars indicate the standard deviation of three obtained single concentrations. Significance levels 
are shown for selected groups and calculated with a one-way ANOVA as *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001. 
The already assumed weakening effect of Lip80-ME in Figure 44 could be confirmed 
by the results of the LDH assay in Figure 45. Despite the observed differences 
between the cytokine levels of samples treated with the needle 
device + microemulsion formulations (Figure 44), no statistically significant 
differences were measured with respect to the LDH release. In case of an application 
without Dermastamp®, PEG-ME showed a significantly higher LDH level compared to 
Lip80-ME. PEG-based ME system presented a slight tendency to have a more 
destructive effect on skin tissue than Lip80-ME. 
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4.3.2 Histological Examinations 
To confirm and complete the immunological results with morphological changes, 
histological examinations were performed. Figure 46 depicts a characteristic image of 
a microneedle channel formed by Dermastamp® into EpidermTM FT skin model.  
 
Figure 46. Histological cryo-section of EpiDermTM FT after piercing 10 x with Dermastamp®. The arrow 
points at one formed microchannel. Upper layers of epidermis (ED), especially the stratum corneum 
(SC) are disrupted. It is apparent that the microchannel is wider at the top and tapers towards deeper 
epidermal layers, but is not deep enough to penetrate to dermis layers (D) lying underneath.  
(Scale bar = 50 µm) 
The presented channel depth was approximately 100 µm. The conical shape of the 
needles and a cutting thickness of 5 µm made it difficult to find a complete channel 
section. SC, the outermost layer of skin was strongly disrupted and the microchannel, 
formed like a cylinder, tapered towards deeper skin layers (chapter 4.2).  
Figure 47 presents H & E stained histological cross-sections of EpidermTM FT. 
Epidermal layers were coloured purplish blue and were well distinguished from the 
pink stained dermal area.  
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Figure 47. Histopathological examination of EpiDerm™ FT skin model after 8 h exposure of (A) PBS 
as mild and (B) 0.8 % SDS as irritating substance. Two arrows in (B) point at mitotically active cells in 
epidermis. (Scale bar = 50 µm) 
Skin samples of PBS and 0.8 % SDS treatment are presented next to each other in 
Figure 47, images A and B. After the application of PBS all layers of epidermis as 
well as of dermis were normally structured and unobtrusive (Figure 47, A). However, 
the treatment with 0.8 % SDS (Figure 47, B) led to severe structural changes. SC 
was compressed in consequence of hyperkeratosis. In comparison to the PBS 
treated sample, the histological slice of SDS treated skin showed an irregular 
layering in the complete epidermal area. Mitotically active cells (arrows, image B) 
indicated high proliferation and led to pathological symptoms of hypergranulosis of 
the stratum granulosum as well as a compact hyperkeratosis of SC. 
The effect of applied formulations in single use and in combination with the needle 
device is illustrated in Figure 48.  
In comparison to PBS sample (Figure 47, A), the application of Lip80-ME (Figure 48, 
A) resulted in a slight hypergranulosis and -keratosis of epidermal layers. An 
enhanced detrimental effect was observed in combination with Dermastamp® where 
a hypergranulosis was emerging, causing thickened epidermal layers especially in 
the stratum granulosum and showing an intradermal blister (Figure 48, B arrow). 
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Figure 48. Histopathological examination of EpiDerm™ FT skin model after 8 h exposure of (A)  
Lip80-ME, (B) Dermastamp® + Lip80-ME, (C) PEG-ME and (D) Dermastamp® + PEG-ME. With 
Dermastamp® treated samples (B) and (D) show more distinct structural changes than (A) and (C). 
The arrow in picture (B) marks an intradermal blister and in image (D) a partially closed microchannel. 
(Scale bar = 50 µm) 
The response to the treatment with reference system PEG-ME is presented in 
(Figure 48, C). A more thickened SC compared to Lip80-ME and a slight 
homogenisation of epidermal layers is shown. With regard to already observed 
histopathological changes of Dermastamp® + Lip80-ME (Figure 48, B), PEG-ME 
combined with piercing step showed an enhanced irritating effect, too (Figure 48, D). 
The skin perforation facilitated penetration of formulations to deeper skin layers, 
resulting in stronger tissue changes.  
Moreover, the combination of Dermastamp® + PEG-ME resulted in a higher irritation 
potential compared to Dermastamp® + Lip80-ME. Image D shows a severely 
damaged skin with many apoptotic cells in epidermis layers. The arrow marks a 
necrotic area that might be a microchannel residue (Figure 48, D).  
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Overall, the application of PEG-ME, with or without Dermastamp® treatment, induced 
a more pronounced cell damage compared to Lip80-ME and confirmed the results of 
histological markers. 
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5 DISCUSSION 
Formulating a protein for the dermal administration is a challenging task. On the one 
hand their high-molecular-weight and flexible, hydrophilic character complicate their 
penetration into skin; on the other hand their sensitive structure to external conditions 
is responsible for a short shelf-life [4]. This thesis focused on the development of a 
topical formulation system which facilitates the application of proteins with a high 
tendency of hydrolysis. Due to their instability in water bacterial collagenases are 
prominent examples and were used as reference. The envisaged dermal application 
system should ensure a high stability and a good solubility of the protein besides 
good spreading and penetration properties as well as a favourable tolerability on 
patients’ skin.  
To prevent enzymatic hydrolysis in an aqueous environment which is corresponding 
to a loss of enzymatic activity, a carrier system based on two separated phases was 
developed. The protein was suspended in the lipophilic-surfactant phase separated 
over the storage time from the aqueous phase. When both phases are mixed just 
before application on the skin, the protein dissolves. Hence, the contact time 
between protein and aqueous phase was reduced to a minimum. A dermal 
formulation forming spontaneously without much energy input and nonetheless giving 
a stable formulation was sought. Microemulsion (ME) systems were promising 
candidates due to their spontaneous formation at room temperature and 
thermodynamic stability [128]. An aqueous solution might be the easiest formulation 
system as it enables a quick dissolution of a protein directly before application on the 
skin. However, the bad spreading as well as penetration and permeation properties 
on skin limit their topical use [129]. Conventional topical dosage forms like creams 
and emulsions presented the desired properties on skin. But a long-term stability of 
creams and emulsions cannot be ensured without high energy input [130,131]. 
Therefore, MEs were the formulation systems of choice. Like emulsions or creams, 
MEs are composed of a surfactant/cosolvent, oil and water phase. MEs can be 
formed when the ratio of oil, aqueous phase and surfactants in the system is 
appropriate. In the present study, a composition of 35 % surfactant/cosolvent, 5 % 
lipophilic phase and 60 % aqueous phase allowed the formation of a ME system 
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(chapter 4.1.1.2). The spontaneous formation and thermodynamic stability of such 
systems might be explained by the low interfacial tension of the surfactant film 
caused by the high content of surface active components (35 %) compared to 
creams or emulsions [65]. Lipoid S LPC 80 (Lip80) was selected as surfactant in 
combination with a short chain alcohol, 2-propanol, as cosolvent, Plurol Oleique CC 
497 (PO CC 497) as lipophilic phase and PBS as aqueous phase. Hoppel et al. 
(2014) emphasised the high polarity of Lip80 which improves solubility in water, 
enhances the self-emulsification power and the ability to form MEs [62]. Lip80 
belongs to the group of phospholipids, a group of natural surfactants with favourable 
properties in topic formulations classified as skin-friendly and permeation enhancers 
[119]. It was intended to support the transport of proteins into the skin via a 
microneedling process. Although microneedling is minimal invasive, it raises the 
requirements for mild and well tolerated formulation excipients. Mild production 
processes and high environmental compatibility along with low irritation potential on 
the skin are frequently named reasons for the utilisation of Lip80 in this thesis [60]. 
Unfortunately, quite a number of nonionic surfactants raise skin irritations, especially 
in the chronical treatment, thus they were inappropriate candidates for the ME 
system [117]. Short chain alcohols like 2-propanol, are suitable cosolvents in 
combination with phospholipids [62]. They make the aqueous phase less hydrophilic, 
enhance the solubility of the phospholipid, shift its HLB to a higher value and enable 
a spontaneous microemulsification [128].  
Short chain alcohols are used as cosolvents due to their affinity to both oil and 
aqueous phase. Likewise, they support the reduction of interfacial tension, which is 
mainly effected by the surfactant, by increasing the fluidity of the interface. Due to 
these properties short chain alcohols are commonly referred to as cosurfactants 
[117]. 2-propanol formed the largest ME areas in comparison to other tested alcohols 
such as propylene glycol and ethanol in ternary diagrams (chapter 4.1.1.1). 
Propylene glycol and ethanol only formed small ME areas, preferably with a high 
content of lipophilic phase. For the purposes of this thesis, a high content of aqueous 
phase (PBS) was necessary to ensure a complete dissolution of at least 1 % model 
enzyme. The combination of 2-propanol and PO CC 497 stabilised the largest ME 
area with the highest PBS content (chapter 4.1.1.2, Figure 21). During formulation 
development it was observed, that the choice of lipophilic component had a 
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considerable influence on ME formation. The ability to stabilise especially hydrophilic 
MEs (high content of PBS) utilising Lip80/2-propanol as surfactant/cosolvent rose 
with increasing hydrophilicity of the chosen oil. This relation is given by an increasing 
HLB value, leading to the following order: LabrafacTM Lipophile WL 1349 (HLB = 1) < 
LabrafacTM PG (HLB = 2) < PO CC 497 (HLB = 6).  
Reducing the amount of lipophilic phase from 10 % to 5 % increased the 
incorporated PBS concentration in MEs even more. The influence of the oil phase on 
microemulsification process was explained by Warisnoicharoen et al. (2000) [132]. 
They described a mechanism in which the hydrophilic groups of oil were interspersed 
in the region of surfactant head group [132]. Therefore, it can be assumed that the 
mentioned PO CC 497 supported the formation of hydrophilic ME best, due to its 
highest hydrophilicity. 
The final choice to apply PO CC 497 as lipophilic phase and 2-propanol as cosolvent 
has been made after preparing a reference ME system with a similar ME area 
compared to MEs based on Lip80. For the reference system, all components and 
their ratios were identical to the phospholipid ME, with exception to the surfactants. 
The high suitability of nonionic surfactants to form MEs was confirmed by the 
application of Polysorbate 80 and Kolliphor® EL in the reference ME. Nonionic 
surfactants are widely used in ME formulations and among them especially 
ethoxylated sorbitan esters (Polysorbates) and sorbitan fatty acid esters (Span®) 
[65,131]. Whether a single surfactant or in combination with further surface-active 
components will enable a spontaneous ME formation, depends on various tests 
(chapter 4.1.1.3, Figure 22). Already the exchange of the surfactants (Lip80 and 
Polysorbate 80/Kolliphor® EL) or different lipophilic components caused considerably 
changed ME areas and demonstrated the variability of these systems. The utilisation 
of 5 % PO CC 497 and Polysorbate 80, Kolliphor® EL/2-propanol formed MEs with a 
high content of PBS as obtained with Lip80, too. Both ME systems allowed the 
formation of hydrophilic ME systems with 60 % PBS which was necessary to dissolve 
1 % of the model enzyme.  
MEs are described as optically isotropic, transparent or slightly opalescent systems 
of low viscosity [116]. Lip80 based ME (Lip80-ME) and Polysorbate 80, Kolliphor® EL 
based ME (PEG) were optically transparent systems with a low viscosity, whereas 
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Lip80-ME was slightly opalescent due to the Lip80. Multiple light scattering (MLS) 
was utilised to differentiate whether it is an optical transparent ME or a turbid 
macroemulsion system. MLS is not reported for ME characterisation in literature yet. 
It is, however, a promising technique to support the first visual inspection of a ME 
with measured data. The high transmission values of protein-free ME formulations 
indicated clear transparent systems (chapter 4.1.2.1, Figure 26). Continuing 
measurements of the systems over 24 h confirmed a stable optical transparency. 
Regarding the application of MEs on skin during tolerability studies the assurance of 
formulation stability is absolutely essential. Tolerability studies on human skin were 
performed over 24 h, hence the stability of MEs were tested over this envisage 
period.  
In literature, two types of microemulsion structures are differentiated which are most 
likely to be formed depending on the composition: bicontinuous ME and droplet-like 
structured ME (classified as oil-in-water, O/W and water-in oil, W/O) [117,129,130]. It 
can be assumed that the amount of 60 % hydrophilic phase in the prepared ME 
induced O/W-ME. Alternatively, the system could also be divided into a 
surfactant/cosurfactant domain (35 %) with partly incorporated oil droplets (5 %) 
besides a large PBS domain resulting in a bicontinuous ME. However, it is also 
emphasised that MEs do not consist of static phases, they are rather characterised 
by a highly dynamic microstructure undergoing continuous and spontaneous 
fluctuations [130,133]. This special structure and their special way of formation make 
an appropriate physicochemical characterisation of MEs a challenging task. The 
inner structure of produced colloidal dispersion was analysed via dynamic light 
scattering (DLS). To calculate the distribution of droplet sizes, parameters like 
dynamic viscosity (mPa*s) or density were determined. As already mentioned  
Lip80-ME and PEG-ME were of low viscosity in comparison to PBS or the viscous 
lipophilic phase PO CC 497 (chapter 4.1.2.2, Table 2). According to Karasulu et al. 
(2008) one problem associated with the topical use of MEs is their fluidity [115]. 
Gasco et al. (1991) addressed this problem with the development of a ME for the 
topical application of azelaic acid [134]. They used Carbopol® 934 as gelling agent to 
increase the viscosity of an O/W-ME system.  
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Crucial within the setting of this project was the applicability of MEs on the artificial 
skin surface in the transwell system. The volume of PEG-ME and Lip80-ME with a 
low viscosity needed to be adjusted to avoid an overflowing of the formulation applied 
onto the skin in the inserts into the basolateral medium. If a larger volume of this MEs 
on skin is envisaged, e.g. to ensure an evenly distribution or to achieve a higher 
protein dose, the addition of thickening agents might be necessary. In examined 
Lip80-ME and PEG-ME the utilisation of Carbopol® 934 is no option because of 
possible ionic interactions between the negatively charged Carbopol® 934 and 
cations in PBS which can induce a protein destabilisation. A more reasonable idea 
would be, e.g. derivates of cellulose ethers, gelatine or guar-based polymers. In all 
investigations described in this thesis, MEs were used without any thickening agents. 
DLS measurements were performed with protein-free MEs. Data of droplet size 
distribution by DLS are popular parameters in scientific research for the 
characterisation of ME systems. Although, the utilisation of DLS in this study 
demonstrated reproducible and stable droplet size distributions over 24 h, these 
investigations were an approach to point out the limitations of this technique 
detecting "characteristic" droplet sizes of a ME (Appendix, chapter 8.3).  
Lip80-ME and PEG-ME showed a bimodal distribution, with a first signal at a droplet 
size of approximately 1 nm followed by a second signal of lower intensity of 20 nm 
(PEG-ME) or 57 nm (Lip80-ME) (chapter 4.1.2.2, Figure 28). Goddeeris et al. (2006) 
identified a signal of surfactant micelles of 11 nm in a 1 % aqueous dilution of 80 % 
Tween® 80 (Polysorbate 80) and 20 % ethanol [135]. Regarding this experience, the 
second signal of PEG-ME may be assigned to surfactant micelles of Polysorbate 80 
and Kolliphor® EL. The second signal of Lip80-ME can most likely be attributed to 
phospholipid micelles, whereas the signal is weaker compared to the signal of PEG-
ME. It is assumed that these differences are owing to mixed micelles created by 
Polysorbate 80 and Kolliphor® EL next to the micelles of Lip80. The first signals at 
1 nm may be caused by the large hydrophilic phases of the ME structures. These 
data must be analysed with high caution because the measured droplet sizes are 
near the detection limit of 0.3 nm of the chosen setup. In literature, ME droplets are 
typically stated in a range of 10 to 140 nm [92,115]. A comparison to the reported 
droplet sizes in literature appeared to be difficult. One reason might be the common 
approach to reduce interparticle interactions via the dilution of original ME which is an 
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incorrect procedure due to changes in microstructure such as droplet disappearance. 
The second reason might be the observed bimodality of PEG-ME and Lip80-ME 
made the calculated z-average diameters based on cumulant analysis inaccurate 
[130,135]. In this thesis, MEs were examined undiluted. The use of concentrated 
systems could then again increase the probability of particle interactions and lead to 
an enhancement of the diffusion coefficient via repulsion effects. It may result in an 
underestimation of the measured droplet sizes because of incorrect calculations 
[130]. The theory of DLS is based on the Stokes-Einstein equation and is related to 
spherical systems [92]. MEs have dynamic, fluctuating droplets which contradicts this 
underlying assumption. Anyway, DLS measurements of colloidal dispersions such as 
MEs are challenging, thus it is necessary to confirm and complement the obtained 
results with findings from other methods. There are various techniques presented 
and controversially discussed in literature. Most often applied are for example static 
light scattering, small angle X-ray scattering, small angle neutron scattering or 
transmission electron microscopy [131,135,136]. Mentioned techniques might be 
interesting to scientific approaches in characterising the microstructure of developed 
MEs but of minor importance in this study. Following investigations focused on the 
potential of MEs as delivery vehicles for the model protein and the tolerability on 
human skin.  
Calculations of the z-average diameter and corresponding distribution curves are 
intensity based and hence very sensitive to the presence of large particles. It was 
envisaged to use this property to detect changes in "size distribution" after the drug 
loading process in MEs. The incorporation of water-soluble catalase as model 
enzyme in the MEs showed a third peak with an increased particle size of 
approximately 400 nm. An increased intensity was detected for the hydrophilic phase 
signal at 1 nm whereas the signal of 20 nm (PEG-ME) and 57 nm (Lip80-ME) 
decreased. Interestingly, measurement repetitions of protein-loaded formulations 
presented fluctuations of dissolved catalase peaks, while the signals of ME structures 
were uniform and reproducible (chapter 4.1.2.2, Figure 29). The observed 
fluctuations might be caused by structural changes of dissolved protein in the MEs. 
The development of a stable protein formulation was a main target of this study 
because destabilisations of protein structure often result in a deactivation as well as 
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loss of therapeutic activity. Therefore, it was necessary to control and complement 
the results of DLS analysis with more detailed protein stability analyses.  
The successful formulation of a protein depends on a thorough understanding of its 
physicochemical and biological characteristics. Several external factors such as pH, 
temperature and interactions with excipients may influence protein activity and 3D 
structure. Changes in activity of an enzyme can be measured via degradation 
processes of a specific substrate. Formulation development with collagenase was the 
initial objective of this thesis. In general, a collagenase activity assay is based on the 
conversion of labelled collagen (substrate) [137]. Active collagenase attacks the 
helical region of the molecule and collagen degradation can be detected [20]. The 
experimental setup and the experiment itself are expensive and time-consuming 
which led to an substitution of collagenase with the model enzyme catalase [21]. 
Catalase degrades H2O2, allowing a fast, easy to measure (UV photometrical) and 
reproducible reaction (chapter 3.2.5).  
The activity of an enzyme highly depends on the conformational stability. Therefore, 
SEC and nanoDSF were performed to study MEs` effect on protein stability, 
specifically on conformational and colloidal changes as well as protein activity. 
Enzyme activity, Rt and Tm of a stable catalase solution at pH 7.0, 25 °C were set as 
control. Decreasing the pH to 3.5 resulted in an instant loss of catalase activity 
(chapter 4.1.3.1, Figure 30). SEC curves underlined this trend showing a 
considerable loss of signal intensity of catalase monomer (chapter 4.1.3.2, Figure 
34). During the activity assay, it was observed that the enzyme precipitated caused 
by unfolding and denaturation processes. Precipitated parts of protein remained on 
the SEC column, reduced the concentration of detectable catalase monomer, and 
decreased the enzyme activity. Furthermore, the SEC diagram of enzyme solution at 
pH 3.5 depicted peaks that eluted later than the monomer and might be assigned to 
peptide fragments. These conformational changes were confirmed by nanoDSF 
analysis showing almost unchanged fluorescence signals and a missing Tm value of 
the treated sample (chapter 4.1.3.3, Figure 37). In addition to the effect of decreased 
pH on protein conformation, changes of colloidal stability were measured as 
increased backscattering intensities. The higher amount of positive charges change 
the ionic strengths of various functional groups of amino acids [53]. Internal forces 
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holding the native catalase structure got lost and the protein unfolded, inducing an 
inactivation. An acidic pH can accelerate hydrolytic reactions. It is reported, that non-
enzymatic fragmentation is usually triggered by hydrolysis of peptide bonds, 
releasing polypeptides of lower molecular weight than the intact protein [55].  
Catalase is a quite heat stable enzyme having a Tm at 56 °C (chapter 4.1.3.3, Figure 
37) [79]. This was confirmed by the detection of a low loss of enzymatic activity 
(30 % in 15 min) at 50 °C (chapter 4.1.3.1, Figure 30). A thermal denaturation with a 
more pronounced unfolding of protein structure was measured at 60 °C. SEC 
analysis underlined this stronger loss of conformational stability at higher 
temperature showing a stronger reduced intensity of catalase monomer and a more 
pronounced additional peak at a later Rt (chapter 4.1.3.2, Figure 34). Switala et al. 
(2002) confirmed this behaviour of catalase as they detected 50 % inactivation at 
65 °C over 30 s [79]. The mentioned pH and temperature stress tests of catalase 
were performed to prove the suitability and sensitivity of selected methods detecting 
inactivation and corresponding structural changes. The gained experiences were 
used to evaluate the enzyme status within the MEs. It was especially challenging in 
SEC measurements because excipients of MEs showed a strong absorption at 
280 nm (chapter 4.1.3.2, Figure 35). However, no signals of excipients interfered with 
the activity assays and nanoDSF analyses. The reason might be the high specificity 
of both techniques. Whereas the activity assay of a protein relies on the degradation 
of a specific substrate, nanoDSF measurements based on the intrinsic fluorescence 
which cannot be found within the excipientsʹ structure. Interestingly, the protein-free 
ME systems presented deviating SEC profiles compared to those performed with 
pure excipients. Lip80-ME placebo eluted as one peak separated from the catalase 
monomer signal. Unlike the uniform SEC profile of Lip80-ME, PEG-ME eluted as two 
peaks, simultaneously to the catalase peak. This was a main drawback analysing 
PEG-ME because the overlapping signals concealed intensity variations as well as 
formations of new peaks caused by structural changes. With increasing incubation 
time, constant alterations of SEC signal indicated modifications of enzyme such as 
aggregates in PEG-ME (chapter 4.1.3.2, Figure 36). Protein aggregates have a 
higher molecular weight than the native structure, thus they eluted earlier than the 
catalase peak. Fluorescence intensity curves of nanoDSF measurements confirmed 
these results showing an unfolded enzyme directly after the preparation of PEG-ME 
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(0 h). Backscattering values increased over time indicating colloidal instabilities as 
they were detected in the SEC curves, too (chapter 4.1.3.3, Figure 39). The loss of 
conformational and colloidal stability of the model enzyme led to a remaining activity 
of approximately 20 % after 24 h (chapter 4.1.3.1, Figure 32). Catalase dissolved in 
Lip80-ME showed a preservation of more than 60 % activity after 24 h 
(chapter 4.1.3.1, Figure 31). SEC curves and backscattering data presented only a 
slight aggregation tendency. The slight time-dependent decrease of activity indicated 
conformational changes like partially unfolded protein molecules which are prone to 
aggregation, too. Nevertheless, a comparison between enzyme stability in PEG-ME 
to Lip80-ME demonstrated a superior stability of model enzyme in the phospholipid 
based formulation. 
But why are catalase inactivation and accordingly limitations of therapeutic activity 
more pronounced in PEG-ME than in Lip80-ME?  
The reason for that can be attributed to the different emulsifying systems, as all 
further excipients were identical. For the preparation of PEG-ME a high concentration 
of 8.75 % Polysorbate 80 and 8.75 % Kolliphor® EL was applied. In general, nonionic 
surfactants are added to protein solutions to prevent aggregation and unwanted 
adsorption, typically used in the range 0.0003 % to 0.3 % [138]. This high 
concentration of overall 17.5 % PEGylated surfactants can counteract the stabilising 
effect by accelerating aggregation via the exclusion of water molecules. PEG 
structures have the property to form hydrogen bonds and to exclude water molecules 
via a steric mechanism from the protein surrounding. They can also interfere with 
hydrogen bonds of the proteins` secondary structure inducing an unfolding [139,140]. 
Chi et al. (2003) reported the effect of nonionic surfactants to preferentially bind to 
unfolded states of protein, resulting in a decrease of native protein stability and in an 
increase of aggregation behaviour [53]. Furthermore, the authors state that 
Polysorbate 80 may contain peroxides which can oxidise sensitive proteins. It is 
conceivable that amino acids within catalase which have a phenolic ring system, e.g. 
tryptophan and tyrosine, are particularly prone to release electrons. Oxidised amino 
acids result in modifications of the protein domain. Until now, it is not completely 
understood to what extent internal electron resources can balance these damages 
and how strong they influence the structure as well as activity of 
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the enzyme [139,141,142]. Lip80-ME is stabilised by a phospholipid with the same 
content of 17.5 %. In literature, the effect of natural phospholipids on proteins is 
difficult to assess due to their inhomogeneous structure with varying fatty acid 
compositions. The composition of phospholipids provides an opportunity for 
hydrophobic as well as polar (e.g. electrostatic) interactions [4,143]. However, the 
initial high inactivation and changes of conformational and colloidal stability make 
PEG-ME unsuitable as vehicle system for catalase. Lip80-ME might be a suitable 
vehicle system for catalase presenting lower interactions and consequently a higher 
activity.  
To classify the type of present protein destabilisations, e.g. size of aggregates, 
optimisations of performed SEC analysis would be needed. These investigations 
could include the use of columns with a smaller pore size increasing the resolution of 
peaks as well as further molecular weight calculations. Additionally, investigations 
such as circular dichroism, X-ray crystallography or NMR may also give residue-
specific information about the destabilised protein structure. However, at first it would 
be necessary to find a method in which the protein can be separated from the ME 
formulation to avoid disturbing signals. The photometric catalase activity assay and 
nanoDSF measurements were insensitive to formulation ingredients and hence more 
eligible. They offered accurate analysis of protein stability besides protein 
aggregation and were crucial for the interpretation of SEC profiles. 
Requirements for the desired dermal formulation system were a high stability of 
model enzyme besides a mild tolerability on human skin. The tolerability studies 
focused on the interaction of pure Lip80-ME in comparison to PEG-ME with human 
skin models. These studies were performed with protein-free MEs. However, the 
application process was performed as it would be necessary for a protein-loaded ME. 
Hence, special requirements had to be considered. The penetration of catalase into 
the skin is limited by the high molecular weight. Passive methods like optimising the 
formulation cannot improve the stratum corneum (SC) penetration to the necessary 
extent, thus active procedures like microneedling have to be used (chapter 2.1.2) 
[10].  
Three commercially available microneedle devices (Dermaroller®, eDermastamp® 
and Dermastamp®) were tested regarding their ability to overcome the SC barrier. 
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The ability of these devices to create pores through the SC was demonstrated by the 
detection of pores via light microscopy (as cross-section) and SEM (as top view). 
SEM pictures were performed with epidermis sheets, whereas the channel depth was 
measured with full-thickness human skin. The depth of created pores varied between 
50 µm for Dermaroller®, 60 µm for Dermastamp® and 120 µm for eDermastamp®. It 
was determined that with increasing channel depth likewise the diameter of 
micropores increased. The observed trend in the microscopic images could be 
confirmed by the results of TEWL measurements. eDermastamp® which created the 
biggest channel depth and largest channel diameter, showed likewise the most 
elevated TEWL values (chapter 4.2.2, Figure 42) A possible explanation is that 
longer needles penetrate deeper through the SC and enter the underlying dermal 
tissue resulting in an increased hydration of SC [144]. Needle shape as well as 
needle size of these devices were identical, therefore the different ways of 
application might be the reason for deviating results. The measurement of TEWL is a 
well-established method to assess the integrity of the skin barrier in vivo, while the 
transfer to in vitro performances with microneedles is limited [108]. On the one hand, 
the sensitivity to micropunctures of the applied open-chamber Tewameter® device 
has to be considered [145]. On the other hand, the punctures may be sealed due to 
cutaneous swelling and result in shallow channel depths [108,146]. Further aspects 
affecting microchannel depth and, likewise with this TEWL changes are skins` 
elasticity, application force and person-to-person variability [6]. Badran et al. (2009) 
detected a reduced pore size in full-thickness human skin 2 h after Dermaroller® 
treatment [104]. The authors emphasised the risk of an overestimation of about 20 % 
due to the usage of separated epidermis for perforation and determination of pore 
sizes [104].  
In this study, an attempt to control these aspects and enable a comparable 
evaluation has been made. The experimental setup was validated regarding its ability 
to produce predictive values: Comparison to a reference device (cannula) showing a 
maximum destruction, repeated measurements and similar hydrated full-thickness 
skin samples (e.g. similar TEWL values of untreated skin) were used. A main 
advantage of the eDermastamp® is the automatically driven piercing step, which 
reduces the reliance on application force and the person-to-person variability. Finally, 
the decisive factor to choose the Dermastamp® instead of eDermastamp® was the 
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limited size and application area of 3D-skin in the transwell system. The 
transferability of the Dermastamp® performance from full-thickness human cadaver 
skin to 3D-skin model was controlled via its ability to create microchannels. An 
elevated channel depth of 100 µm in the transwell system compared to 60 µm in 
human skin was measured. This result can be explained by the reduced mechanical 
barrier properties of 3D-skin next to ex vivo human adult skin [147,148]. It indicates a 
major weakness of reconstructed skin models which should be considered in order to 
avoid an overestimation of results in comparison to the in vivo situation.  
Lip80-ME was designed for the topical application and therefore needs to be non-
irritating on the human skin. In this thesis, the focus was set on the examination of 
the effect of Dermastamp® + Lip80-ME next to Dermastamp® + reference ME 
(PEG-ME) on human skin. Historically, the irritation potential of topical products was 
investigated in animal models for safety assessment followed by in vivo studies with 
healthy volunteers [122]. The Draize rabbit primary dermal irritation test was routinely 
used for the preclinical determination of skin irritational potentials [149]. The 
relevance of animal irritancy data to the human situation is questionable and can lead 
to misinterpretations [122,148]. Animal tests are ethically not justifiable for this 
research utilisation. Furthermore, there are several possibilities to replace them. One 
promising alternative are human in vitro skin models which were first developed in 
the early 1990`s and gained importance with the adoption in general guidelines as 
COLIPA, 76/768/EEC, ICH S2 (R1) and OECD 431/439 [85,150–154]. They mimic 
the human skin to a high extent. A variety of reconstructed human skin models are 
on the market allowing various applications like skin corrosion or irritation tests 
(chapter 0). In addition, they enable the investigation of pathological effects (e.g. skin 
cancer) as well as physiological effects (e.g. wound healing) [85]. Commercially 
available skin models have a highly reproducible tissue quality. On the contrary, 
there are some drawbacks, as missing skin appendages (sweat glands, hair 
channels), the indirect endpoint estimation (immunological response instead of 
erythema/oedema manifestation) and the already mentioned impaired barrier 
properties, as well [147]. Lip80-ME and the reference ME (PEG-ME) were applied on 
a commercially available model, EpidermTM FT 400. This full-thickness skin tissue, 
which matches the in vivo situation closely, was selected to examine the release of 
immunological markers [155].  
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Acute and chronic skin irritations are local and reversible inflammatory responses of 
normal living skin to external stimulants [122]. Skin irritation is a complex 
phenomenon that involves resident epidermal cells, dermal fibroblasts, endothelial 
cells and invading leukocytes. They all communicate with each other via cytokines 
and lipid mediators. Various parameters (IL-1α, IL-6, IL-8 release; cytotoxicity and 
skin morphology) reflecting irritancy and were examined in this study with 
EpidermTM FT. To evaluate the level of irritation, ME samples were compared to a 
negative and positive control. According to manufacturers’ protocol, PBS pH 7.0 was 
applied without any further treatment as a negative control [109]. SDS is commonly 
used in tolerability studies as positive control due to its ability to induce a contact 
dermatitis. Pre-investigations demonstrated a strong destruction of skin tissue after 
the treatment with ≥ 1 % SDS solution. Therefore, a 0.8 % solution of SDS was used 
as a positive control in this setup showing an irritant potential with a moderate cell 
destruction [122,156]. All examined immunological markers (IL-1α, IL-6, IL-8 and 
LDH) presented a significant difference between the negative and positive control. 
Pathohistologic examinations confirmed these results and concurrently the suitability 
of the chosen setup to distinguish between mild and irritating substances.  
The primary function of keratinocytes is to provide structural integrity and barrier 
function of the epidermis. They become a key part of the initiation and perpetuation 
of skin inflammation and immunological reactions by the release of cytokines [26].  
IL-1α is constitutively produced by keratinocytes and stimulates its own release as 
well as the production and release of secondary cytokines (e.g. IL-6, IL-8). IL-8 is 
secreted especially after mechanically induced cell damage while IL-6 is secreted 
after exposure to chemical noxae. According to the experiences of other authors, it is 
possible to differentiate between a mechanically or chemically induced irritation, if 
both markers are assessed [126]. The combination of MEs with Dermastamp® did not 
increase the release of secondary cytokines compared to the sole application of ME 
(chapter 4.3.1, Figure 44). IL-6 showed reduced concentration levels when the 
microneedle device was applied with the MEs compared to applying the microneedle 
device only. This weakening effect of MEs after microneedling was observed to be 
significant just after Lip80-ME was applied. Concentration profiles of IL-8 presented a 
similar trend, however, the interleukine release of Dermastamp® compared to 
Dermastamp® + MEs was not significantly different. IL-1α concentrations of 
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Dermastamp® and Dermastamp® + PEG-ME were on a similar low level comparable 
to those of the PBS sample (chapter 4.3.1, Figure 43). Their IL-1α concentration was 
reduced in comparison to the levels of solely applied MEs. In contrast, the 
combination of Dermastamp® + Lip80-ME showed significantly increased IL-1α 
concentrations compared to those achieved by applying the SDS solution. This 
development contradicts the observed weakening effect of Lip80-ME on the 
microneedling process in IL-6 and IL-8 profiles and underlines the weakening effect 
of PEG-ME. One explanation might be the initialising function of IL-1α in an 
inflammation process. IL-1α release increases directly after an irritating stimulation 
[157]. During an ongoing inflammation process the release of IL-1α decreases again 
caused by a negative feedback mechanism. This inhibition is stimulated, inter alia, by 
secondary cytokines like IL-6 [18,39]. IL-6 is an important regulating cytokine 
effecting pro- and anti-inflammatory reactions. It stimulates the synthesis of  
IL-1-receptor antagonist (IL-1-ra) which competitively inhibits IL-1 receptor and thus 
reduces the secretion as well as the inflammatory effect of IL-1α. With respect to the 
presented results, a lower negative feedback for Dermastamp® + Lip80-ME can be 
assumed because of a lower secondary cytokine release, consequently resulting in 
higher IL-1α levels.  
It was envisaged to control the tolerability of application systems on human skin over 
a prolonged contact time which induced extreme conditions. The manufacturer of 
skin models recommended 24 h as the maximum exposure time for a good 
performance in tolerability studies. An evaluation of media samples (IL-6 and IL-8) 
after 24 h exposure time was performed but led to incorrect sample concentrations 
and missing reference values of the SDS sample. Due to the already mentioned 
detrimental effect of SDS solution the permeability of skin tissue increased over time 
and facilitated the contact between sample and basolateral medium. SDS reduced 
the number of active cells and interfered with the detection of immunological 
markers. During 24 h exposure time, MEs were not removed from the tissue surface. 
The formulations got also in contact with the basolateral media, interfered with the 
cytokine assays and induced decreased concentrations. However, IL-1α was not 
detected in the basolateral media, this cytokine was detected after tissue lysis. As it 
is a destructive procedure this assay was performed at the end of tolerability studies, 
thus after 24 h. It is conceivable, that the delayed examinations after 24 h of IL-1α 
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instead of 8 h for IL-6 and IL-8 supported the detection of negative feedback 
reactions. 
A differentiation with the results of secondary cytokines between chemically and 
mechanically induced skin damages was not possible due to similar concentration 
profiles of IL-6 and IL-8. This led to the assumption, that the observations from 
literature did not fit to the present model or the chosen settings e.g. measuring time 
was unsuitable [124,126]. Besides the detection of IL-8, one parameter for cell 
damage is the integrity of cell membranes. LDH is a stable cytoplasmic enzyme 
present in all living cells. It is released into basolateral cell culture media upon 
damage of the plasma membrane [127]. As it was expected, the microneedling 
process showed the highest LDH concentration (chapter 4.3.1, Figure 45). According 
to the observed weakening effect of Dermastamp® + PEG-ME and 
Dermastamp® + Lip80-ME (IL-6, IL-8 and IL-1α), the LDH release was significantly 
decreased compared to the solely applied device as well. With the performance of 
histological examinations, it was possible to detect and proof the previously assumed 
distinctive properties between Lip80-ME and PEG-ME on human skin (chapter 4.3.2, 
Figure 47 and Figure 48). While the tissue of Dermastamp® + Lip80-ME was slightly 
irritated, the damage following the application of Dermastamp® + PEG-ME was 
tremendous. Skin layers of Dermastamp® + PEG-ME treated sample were strongly 
homogenised, exhibiting numerous apoptotic cells.  
A comparison between histological and immunologic analyses leads to the question: 
How are destroyed and apoptotic cells able to release cytokines? 
It is impossible and for this reason induced false negative results for the combination 
of Dermastamp® + PEG-ME. The common property of ME formulations to reduce the 
irritating effect after microneedle treatment is only correct for the phospholipid-based 
ME. Detected IL-6, Il-8 and IL-1α levels of Dermastamp® + PEG-ME are reduced 
because of destructed as well as dead cells that are not able to release cytokines. 
The reduced LDH concentration following Dermastamp® + PEG-ME application 
despite the high number of damaged cells can be explained by the test procedure. 
ME formulations were not removed during the 24 h measuring time. With elapsing 
time, the cellular leakage increased and PEG-ME got into contact with the 
basolateral medium. It is reported in literature that surfactants (PEG-ME includes 
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17.5 % of nonionic surfactants) are able to interact with the enzyme and degrade its 
function [127,158]. This may be led to the faulty contemplation of a low LDH release.  
Lip80-ME did not get into contact with the basolateral medium because of an intact 
skin structure and did not reduce the LDH concentration. The induced weakening 
effect of Lip80-ME on microneedling process can most likely be attributed to the used 
phospholipid. It is a biological surfactant and a major component of membrane lipids 
[60]. Regarding to this property it is conceivable that Lip80 can stabilise damaged cell 
membranes and likewise reduce the immunological reaction. 
Lip80-ME demonstrated superior protein stability and favourable properties on 
human skin. It can be used as an attractive topical vehicle system to reach a 
therapeutic protein concentration in certain skin layers or in the blood circulation. The 
large amount of surface active substances and the additive of a short chain alcohol 
have a penetration enhancing effect via decreasing the resistance of upper skin 
layers. The high content of an aqueous phase might be able to enhance the 
hydration effect of the stratum corneum and likewise the percutaneous absorption of 
the protein. The transport of protein through the skin might also be enhanced by the 
similarity between phospholipid structures and the barrier layers of the skin 
[65,117,129]. Nonetheless, it is necessary to support the transport of a protein 
through the SC via a microneedling step or a comparable technique. In this thesis, 
the application of the needle device increased the penetration of each test 
formulation into the skin. In addition, Lip80-ME presented the special characteristic of 
a weakening effect on skin tissue after an induced damage.  
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6 CONCLUSION 
The presented work highlights the challenges accompanying the development and 
characterisation of a dermal protein delivery system. For the first time a phospholipid-
based ME was applied and evaluated after a microneedling step on a reconstructed 
human skin model. 
The first aim of this thesis was the development of a formulation system, which 
enables the dermal application of an enzyme with a hydrolytic sensitivity. A 
phospholipid based pre-ME concentrate was found to be most suitable as it reduces 
the contact time between the enzyme and hydrophilic phase. The enzyme is 
suspended in the lipophilic-surfactant phase, separated from the hydrophilic phase. 
Just before application on the skin both phases are mixed to form the final ME. Lipoid 
S LPC 80 (Lip80), a phospholipid, facilitated a spontaneous formation of a stable ME.  
Lip80-ME demonstrated a superior stability of the model enzyme compared to a 
PEGylated reference ME system (Polysorbate 80 and Kolliphor® EL). Directly after 
preparing the final PEGylated ME, the dissolved enzyme showed strong 
conformational changes as well as changes in the colloidal stability associated with a 
significant loss of activity. Lip80-ME presented no considerable interactions with the 
model enzyme and is therefore ideally suited as vehicle system for proteins. In 
general, the dissolution of a protein is a critical processing step, especially in an 
aqueous environment [159]. The current study used catalase as model enzyme 
(instead of collagenase), but the pre-formulated Lip80-ME concentrate might be a 
promising vehicle system for other proteins as well. 
Detecting the protein stability within a formulation is more challenging than within a 
simple composed buffered solution due to various possibly interfering excipients. In 
this thesis, the utilised enzyme activity assay and nanoDSF measurements led to 
conclusive results independent of interfering excipients. Thus, the direct 
determination of protein stability of complex systems without further purifications 
could be demonstrated. These approaches can be transferred to stability 
examinations for other protein formulations. 
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The second aim of this thesis was the enhancement of protein transport into human 
skin via a suitable microneedle device. Dermastamp® was chosen over two other 
commercially available microneedle devices because it is the most efficient, 
reproducible, and applicable device in studies with the utilised human skin model. 
Finally, the combination of Lip80-ME and Dermastamp® was examined on 
reconstructed human skin equivalents to predict the in vivo tolerability. These skin 
tolerability studies were performed in comparison to the PEGylated reference 
formulation. The effects of MEs and Dermastamp® on skin tissue was analysed by 
the detection of inflammatory markers and pathohistological investigations. These 
examinations demonstrated the ability of phospholipid based ME to decrease the 
irritation effect caused by the microneedle device. Furthermore, its reaction on skin 
was milder compared to the detrimental effect of the reference formulation  
(PEG-ME). These observations underlined the importance of pathohistological 
examinations next to immunological assays and their complementary functions. 
Nevertheless, the elevated permeability of reconstructed skin relative to native 
human skin must be considered for both methods to avoid an overestimation of 
observed results [148]. Until now, skin equivalents cannot completely replace in vivo 
studies, but they are important to assess the tolerability in first screening steps of 
chemicals as well as early states of formulation development. The possibility of a 
new application for human skin models besides their versatile applicability was 
presented.  
This thesis presented new scientific findings in the field of dermal drug delivery and 
revealed approaches for additional investigations. Further tests (e.g. with a special 
focus on the weakening effect of Lip80-ME after skin disruption) could be used to 
analyse the correlation between the phospholipid composition like the amount of 
MAPL and DAPL. Additional experiments with 3D-skin equivalents, including wound 
healing studies, can be utilised to characterise the nature and likewise the 
effectiveness of the observed weakening effect. The therapeutic activity of 
phospholipids in addition to their emulsifying properties would open the way for new 
and innovative fields of application.  
However, the nonirritating potential of phospholipid ME as anticipated at the 
beginning could not be unconfirmed. The longer the exposure time, the higher the 
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immunological response of Lip80-ME compared to PBS. Further investigations can 
focus on the irritating/immune-activating potential to elucidate whether the 
formulation is suitable for dermal vaccination. It is conceivable that the ME may act 
as vehicle system for the antigen and simultaneously as an immune adjuvant 
supporting the immunisation. Arya et al. (2015) and Shakya et al. (2015) emphasised 
the effectiveness of dermal vaccination in combination with a microneedle device. 
These authors showed that microneedles are suitable for cutaneous allergen specific 
immunotherapy and that this method is more effective than common subcutaneous 
injections [160,161]. Treatment with microneedles has several advantages such as 
the self-application of reproducible amounts of drugs without medical assistance, 
painless application on a large surface area and no scar formation. This would be 
especially important in developing countries or in the treatment of children [17,160]. 
Dermal vaccination is a promising and challenging research area with great need for 
innovative application systems. A phospholipid-based ME combined with a 
microneedle device is a new method for a simple and easily produced system in 
comparison to the current research methods that employ complex microneedle 
coating processes [33].  
Lip80-ME is a promising vehicle system for dermal protein delivery. Targeted studies, 
including biopharmaceutics and pharmacological effects, will be part of continuing 
research.  
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8 APPENDIX 
8.1 Buffers 
 
8.1.1 50 mM Phosphate Buffered Saline pH 7.0 
Ingredients   
K2HPO4 x 3H2O 
(Sigma Aldrich Chemie GmbH, 
Steinheim, Germany) 
11.42 g/L 
 
8.1.2 50 mM Phosphate Buffered Saline pH 7.0; Modified 
Ingredients   
K2HPO4 x 3H2O 
(Sigma Aldrich Chemie GmbH, 
Steinheim, Germany) 
11.42 g/L 
L-arginine hydrochloride 
(Sigma Aldrich Chemie GmbH, 
Steinheim, Germany) 
42.13 g/L 
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8.1.3 Tissue Lysis Buffer 
Ingredients   
MgCl2 
(Sigma Aldrich, Saint Louis, US) 
15 mmol/L 
HEPES 
(dry powder) 
50 mmol/L 
NaCl 
(Sigma Aldrich, Saint Louis, US) 
150 mmol/L 
Urea 
(Sigma Aldrich, Saint Louis, US) 
8 mol/L 
Triton X-100 
(Merck KGaA, Darmstadt, Germany) 
0.1 % (m/m) 
Add one SigmaFast Inhibitor Cocktail Tablet (Sigma Aldrich, Saint Louis, US) to 
20 mL lysis buffer.  
500 µL of the final mixture is able to inhibit 0.5 g tissue (calculated with 
manufacturer`s protocol). 
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8.2 Size Exclusion Chromatography-Method 
 
Stationary Phase: PSS PROTEEMA analytical 300 Å, 5 µm 
 
Mobile Phase: 50 mM phosphate buffered saline pH 7.0; 
modified 
add 0.05 % (m/m) NaN3 
pH adjusted with 1 M HCl 
 
Flow Rate: 0.7 mL/min 
 
Injection Volume: 50 µL 
 
Detection Wavelength: 280 nm 
 
Detection Sensitivity: 0.02 
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8.3 Dynamic Light Scattering-Stability Analysis 
 
 0 h 24 h 
 z-average PDI z-average PDI 
Lip80-ME 1.20 0.29 1.15 0.26 
PEG-ME 1.40 0.50 1.43 0.50 
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